Podcasts about vitadao

In this episode of LEVITY, we speak with Laurence Ion, a tech entrepreneur whose experience with a rare genetic disease led him to tackle one of humanity's greatest challenges: aging.Starting as a shy coder who 'couldn't talk to strangers,' Laurence has become a movement leader pioneering a bold new approach: creating specialized cities where extending human lifespan isn't just a goal - it's the future of humanity.-- EPISODE HIGHLIGHTS --✅ Laurence's personal journey with multiple hereditary exostoses and how it shaped his perspective on aging and mortality.✅ The founding and evolution of VitaDAO, a decentralized science organization funding longevity research.✅ How crypto-based communities are accelerating anti-aging research outside traditional funding models.✅ The concept of special jurisdictions for medical innovation where regulatory frameworks can move at "warp speed".✅ Viva City's vision to create physical communities and hubs focused on longevity.✅ The $2 million recursive finder's fee for anyone who helps secure a location for the first major Viva City jurisdiction.✅ How living in community environments like Zuzalu and Aevitas House naturally promotes healthier lifestyle choices.✅ The Frontier Tower project - a 16-story "vertical village" designed for longevity-minded living.✅ JellyfishDAO's mission to change cultural narratives around aging through film and media.✅ The relationship between AI advancement and longevity research.✅ How decentralized clinical trials could dramatically reduce the cost and time of bringing treatments to people.✅ Real-world examples of companies already offering experimental longevity treatments in special jurisdictions. Hosted on Acast. See acast.com/privacy for more information.

What if the future of healthcare lies in our ability to decentralize it? This episode takes us on an insightful journey with Jasmine Smith, the visionary CEO of Rejuve AI. She shares her fascinating transition from health information management to leading a groundbreaking project in decentralized health and wellness. The transformation from Web 2.0 to Web 3.0 is laid bare, with Jasmine revealing how this evolution empowers individuals by taking control away from traditional central entities and addressing challenges like scalability and user experience. We also uncover how technologies such as IPFS and Filecoin are poised to revolutionize sectors like healthcare, particularly in data handling and security.We venture into the intersection of AI, blockchain, and longevity research through Rejuve AI's decentralized platform. This network ambitiously crowdsources health data from users, leveraging wearable devices and health surveys, with future plans for genomic data integration. By personalizing health protocols, Rejuve AI aims to deepen users' understanding of their physiological data, marking a significant stride toward democratizing health information. There's a burgeoning movement toward decentralized science, with comparisons drawn to initiatives like Matt Kaberlein's crowdsource database for rapamycin and VitaDAO's innovative research efforts.As we explore decentralized science further, the episode delves into how it fosters fairness, reduces bias, and accelerates research, especially in the field of aging. VitaDAO's novel approach to funding biotech startups through tokenized intellectual property is highlighted, offering a glimpse into the future of rapid therapy development. The synergy between VitaDAO and Rejuve AI is palpable, with both entities pushing the boundaries of health innovation. Listeners can anticipate the launch of the Rejuve AI app in early 2025, a tool designed to enhance user health and longevity through a freemium model backed by the RJV token. These initiatives are set to transform healthcare into a more collaborative and data-driven industry, promising a healthier future for all.https://www.rejuve.ai/Free sample chapter -Lies I Taught In Medical School :https://www.robertlufkinmd.com/lies/Our sponsors: Complete Metabolic Heart Scan ($100 off with 'LUFKINCT') https://robert-lufkin.mykajabi.com/CMHS Siphox Health, at-home health testing (15% off):https://pathlongevity.com/Prolon & the Fasting Mimicking Diet (20% off ):https://prolonlife.com/Lufkin *** CONNECT***Web: https://robertlufkinmd.com/X: https://x.com/robertlufkinmdYoutube: https://www.youtube.com/robertLufkinmdInstagram: https://www.instagram.com/robertlufkinmd/LinkedIn: https://www.linkedin.com/in/robertlufkinmd/Facebook: https://www.facebook.com/robertlufkinmd Threads: ...

Today Jason is exploring all things DeSci. In this episode Jason is joined by BIO Protocol's CEO & Co-founder Paul Kohlhaas, as well as VitaDAO's Co-lead Alex Mukhin. In this episode we discuss: What exactly is DeSci? What is VitaDAO? How is VitaDAO set to increase human longevity How does crypto solve medical research? Medical investment incentives What is VITA-FAST? How is development enforced What are the traditional medical investment dynamics? Is DeSci a hype cycle? What is pump.science & $RIF? DeSci's roadmap And much more! Host: Jason Choi @mrjasonchoi . Not financial advice. -- Tangent is a private holdings company managing personal assets and is not a licensed investment advisor nor does it manage or accept any external capital. Nothing discussed is a solicitation for investment and is for entertainment purposes only. -- Timestamps: (00:00) Introduction (02:28) What is DeSci? (03:35) Paul's background (07:27) VitaDAO user experience (09:34) VitaDAO's use case (12:17) How does crypto solve medical research? (16:44) VitaDAO demographic (19:50) Investment incentives (24:09) VITA-FAST (27:05) Development enforcement (32:14) Traditional medical investment dynamics (35:07) Is DeSci a hype cycle? (40:08) What is pump.science & $RIF? (45:22) DeSci roadmap (49:35) Outro -- Twitter accounts: Jason Choi: https://twitter.com/mrjasonchoi Alex Mukhin: https://x.com/alex__mcl Paul Kohlhaas: https://x.com/paulkhls Blockcrunch: https://twitter.com/theBlockcrunch -- Blockcrunch VIP: https://blockcrunch.substack.com/ -- Disclaimer: The Blockcrunch Podcast (“Blockcrunch”) is an educational resource intended for informational purposes only. Blockcrunch produces a weekly podcast and newsletter that routinely covers projects in Web 3 and may discuss assets that the host or its guests have financial exposure to. Views held by Blockcrunch's guests are their own. None of Blockcrunch, its registered entity or any of its affiliated personnel are licensed to provide any type of financial advice, and nothing on Blockcrunch's podcast, newsletter, website and social media should be construed as financial advice. Blockcrunch also receives compensation from its sponsor; sponsorship messages do not constitute financial advice or endorsement.   Full disclaimer:  https://blockcrunch.substack.com/about

In this episode, we look at some low cap altcoins in the desci category. Many investors are betting big on this sector going in the 2025 Crypto Bull Run. Projects like VitaDAO, Research Coin, Lake and more. ➡️  Trade with Josh - https://t.me/+vS5uDtG57XpjNDA1

In this episode of the Aging Science Podcast by VitaDAO, we explore the connection between environmental pollution and longevity with Dr. Dushani Palliyaguru. Delve into the Nrf2 pathway, a critical mechanism for cellular defense, and discover the benefits of sulforaphane from broccoli as a potent Nrf2 activator. Dr. Palliyaguru, a renowned expert in aging and disease prevention, shares her extensive research on how environmental toxins affect health and longevity. Learn about innovative strategies to combat pollution-related health risks and enhance lifespan through nutritional interventions and scientific advancements. Join us for an insightful conversation on promoting longevity in a polluted world.

Episode Description: Karl and Erum discuss the state of health and technology with Laura Minquini of AthenaDAO, focusing on advancements in women's health research and quantum computing. Be sure to tune in to this conversation to hear about the importance of reproductive longevity, the challenges faced in women's health research, and the role of decentralized science. Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything from sustainable ingredients to high performing materials. Biology is the oldest technology. What are we growing? JOIN OUR BIOCOMMUNITY. BECOME A PATREON.  ⁠START HERE⁠. Chapters: 00:00:00 - Natural Health: The Real Deal 00:00:23 - Summer Thrills and Memorial Day Escapades with Erum and Karl 00:02:49 - Brooklyn's Cultural Pulse: Events and Highlights 00:05:17 - Listener Shoutouts: Your Voice, Our Podcast 00:06:51 - Quantum Computing Exposed 00:09:13 - Quantum Computing: Transforming Biotechnology 00:12:55 - Women's Health Meets Decentralized Science: Welcome Laura Minquini 00:18:27 - Women's Health Funding: Smashing Barriers 00:24:35 - Reproductive Longevity: Key Challenges and Gaps 00:30:42 - Pioneering Approaches to Decentralized Science 00:36:05 - DAOs: Expanding Reach and Impact 00:37:08 - Women's Health Research: Comprehensive Analysis 00:39:36 - Revolutionary Advances in Reproductive Tech 00:40:44 - Women's Health Research: Future Directions and Funding 00:41:29 - Streamlining DAO Operations for Success 00:44:13 - Community-Driven Science: Powering Women's Health 00:47:02 - Athena DAO: Success Stories and Milestones 00:51:27 - Get Involved: How You Can Make a Difference 00:55:00 - Join the Athena DAO Movement 01:01:29 - Final Thoughts and Future Vision Episode Links: AthenaDAO (link) Laura Minquini on X (link) Plates for Change Nonprofit (link) Seth Yakatan on LinkedIn (link) StarTalk Episode on Quantum Computing (link) Quantum Supremacy by Michio Kaku (link) Drew Berry Animations (link) VitaDAO (link) LabDAO (link) DeSciNYC (link) Topics Covered: biotech funding, biopharma, venture capital, biology, startup, entrepreneurship, women's health, reproductive longevity, DAO, decentralized autonomous organizations, blockchain, Femtech Have a question or comment? Message us here: Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠GrowEverything website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email: groweverything@messaginglab.com Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message

In the current episode of The VitaDAO Aging Science Podcast, we dive into the intricate world of rapamycin, caloric restriction, and inflammaging with the distinguished Dr. Arlan Richardson. Dr. Richardson, a pioneer in aging research with a career spanning over five decades, shares his extensive knowledge and groundbreaking insights. We discuss his pioneering work on rapamycin, the complexities of caloric restriction, and the role of chronic inflammation in aging. This episode also touches on the significance of necroptosis, the intriguing connections between senescence and inflammation, and the future of aging interventions. Join us as we explore these vital topics and their implications for human longevity, shedding light on the critical role of preclinical studies in advancing our understanding of aging.

In the current episode of The VitaDAO Aging Science Podcast, we explore the fascinating intersection of entropy, epigenetics, and aging with our esteemed guests, Peter Fedichev, founder of Gero and a trailblazer in longevity research, and Prof. Jan Gruber from Yale-NUS, known for his deep understanding of the physics behind aging. As we navigate through Peter Fedichev's recent paper that sparked heated discussions on the limits of age-reversal, we'll delve into the science of stochastic changes in methylation patterns, the controversial debate around the reversibility of aging, and the impact of entropy on human longevity. This episode will also shine a light on the vital role of VitaDAO in science funding, the challenges faced by PhD students in today's economic climate, and the exciting potential of naked mole rats in aging research.

How compatible are two very different giants in the longevity movement? Aubrey de Grey, the iconic and highly academically decorated bioscientist, paved the way for the early stages of scientific development, and Bryan Johnson, the software mogul turned one-man experiment and chief meme officer of longevity, focuses on the intersection of lifestyle and research.Do their very different approaches go together?They do! Let's explore how they overlap with each other and how they are giving shape to the longevity movement. They navigate the intricate landscape of scientific advancement, with Aubrey opening the area of possibility through scientific progress and Bryan developing broader accessibility of solutions.Advancing From Early Stage DiscoveryIn society, when someone demonstrates what's possible, it inspires others to follow suit. “My goal is to shift the current trend from being offensive, weird, and eccentric to being amazing through Blueprint.” – Bryan JohnsonChange is inevitable because humans tend to doubt new technologies initially, but once they're available and add value to people's lives, adoption grows, and it becomes the new normal. This is a recurring pattern in history; therefore, we should question our initial skepticism.Collaborations With The Traditional Clinical SidesWorking together with clinicians is crucial. PhDs and MDs have different approaches, but they both understand the end goal: reducing human suffering. The process from lab to clinic is rocky and time-consuming, but there are pathways to streamline and accelerate. Although people like Bryan Johnson play a significant role in advancing the mainstream medical profession, they intelligently contribute by collecting relevant data to expedite the process of ensuring the safety and effectiveness of medical innovations, making them accessible to a wider audience beyond just the early adopters.Why Hasn't There Been A Moonshot For Longevity Yet?Traditionally, the Far East has been slower to embrace longevity research despite factors like respect for the elderly, demographic challenges, and technological prowess. Recently, this mindset might be changing, and if so, it could pave the way for a significant initiative akin to the Apollo project. One hurdle in the West is the centralization of science funding.  Public officials act based on a desire for re-election and public opinion, but the public has a presumption against new technology. The solution could be more independent science funding, such as VitaDAO, and more “direct democracy,” such as citizen science.  Aubrey's innovation and Bryan's practical focus signify the diverse strategies required for advancement, emphasizing the integration of discovery, clinical application, and societal acceptance of mainstream longevity technologies. Despite cultural and political challenges, this fireside chat underscores the potential for transformative initiatives and the necessity of collective action in propelling the longevity movement forward. Get full access to Stranded Technologies at niklasanzinger.substack.com/subscribe

n the upcoming episode of The Science of Aging Podcast, we dive deep into the critical questions surrounding mouse models in aging research with our special guest, Dr. Dan Ehninger from the German Center for Neurodegenerative Diseases (DZNE) in Bonn. Dr. Ehninger, a visionary in the field of biogerontology, brings to the table his controversial and thought-provoking perspectives on the limitations and potential pitfalls of relying on mouse models for understanding human aging. We'll dissect the intricacies of rapamycin and caloric restriction studies, the debate over the mouse model's relevance to human aging, and innovative approaches to designing more effective mouse studies. This episode is a journey into the foundational challenges of aging science, highlighting the need for robust, translational research strategies. Join us for a riveting discussion that promises to enlighten, challenge, and inspire our understanding of the path forward in aging research.

n this episode of The VitaDAO Aging Science Podcast, we're excited to host Prof. Rudolf Wiesner, an esteemed figure in the field of mitochondrial biology. As a key member of the CECAD Research Center at the University of Cologne, Prof. Wiesner's research has significantly advanced our understanding of mitochondrial dysfunction and its impact on aging. In our conversation, we'll explore his insightful work on mitochondrial DNA deletions, the innovative concept of mitochondria-derived vesicles, and the pivotal role of mitochondria in cellular aging and organ dysfunction. Prof. Wiesner will share his latest findings on the mutation rates in mitochondrial DNA, the intriguing enzyme TWINKLE, and the critical function of the adrenal medulla in mitochondrial quality control. Get ready for a profound discussion that sheds light on the complex relationship between mitochondria and the aging process, offering new perspectives on therapeutic strategies to slow aging and improve healthspan

In this episode of The VitaDAO Aging Science Podcast, we are thrilled to welcome Prof. Björn Schumacher, a leading expert in genome stability and aging. As Director of the Institute for Genome Stability in Ageing and Diseases at the University of Cologne, Prof. Schumacher has pioneered research into how DNA damage influences the aging process and the development of age-related diseases. We'll dive deep into his groundbreaking discovery of novel methods to enhance DNA repair, and how this could revolutionize our approach to extending healthy lifespan. Expect a captivating discussion on the intricacies of DNA repair mechanisms, the role of the DREAM complex, and the potential of new therapies to combat aging at the molecular level. Prepare to be enlightened by Prof. Schumacher's insights on the cutting-edge of aging science

In the upcoming episode of The Science of Aging Podcast, we're set to explore aging research with Dr. Jesse Poganik and Dr. Mahdi Moqri, just before the 2023 Biomarkers of Aging Symposium. Dr. Poganik from Brigham and Women's Hospital and Harvard, and Dr. Moqri, a joint fellow at Harvard and Stanford, will share insights on biomarkers and omics in longevity studies. We'll discuss the importance of biological clocks, functional markers, and the impact of these findings on aging interventions. Tune in for a concise yet deep dive into the future of personalized health and aging research.

Eleanor Davies, Dealflow Steward at VitaDAO, Alex Colville, Co-founder and General Partner at age1, and Patrick Burgermeister, Expert in Life science Investing at Kizoo Technology Ventures, join Phil Newman, Editor-in-Chief at Longevity.Technology, for a panel discussion at Investing in the Age of Longevity 2023. In their chat, participants outline the investment strategies and business models of their respective funds in the longevity sector, as well as their expectations for 2024. Investing in the Age of Longevity 2023 was held on 16 November 2023. The masterclass featured presentations from scientists and business leaders at the cutting edge of the field, giving participants the inside track on the latest aging-related discoveries and investment opportunities. For more investment and economics analysis plus inspiration please visit our website masterinvestor.co.uk.

In this installment of The VitaDAO Aging Science Podcast, we embark on a journey through the complex terrain of human genetics and aging with Dr. Joris Deelen. Broadcasting from the dynamic setting of the ARDD conference in Copenhagen, we dive into a rich and enlightening conversation about the limitations and revelations of using mice as model organisms in aging research. Dr. Deelen, a renowned researcher in the field of genetic longevity, brings his extensive knowledge and unique perspective to our discussion. Together, we explore the intriguing discrepancies between human genetic data and mouse models, shedding light on what these differences mean for our understanding of aging. Dr. Deelen shares his insights from his groundbreaking work at the Max Planck Institute for Biology of Ageing, particularly his research on genetic variants linked to human longevity. We delve into the nuances of GWAS studies, the mystery of missing heritability in aging, and the fascinating case of ApoE in longevity research. This episode is a treasure trove for anyone interested in the genetic underpinnings of aging, the potential of human genetic studies to unravel the secrets of longevity, and the future directions of aging research. Tune in to gain a deeper understanding of how genetics shapes our journey through life and the exciting possibilities that lie ahead in the quest for extended healthspan and lifespan.

In this episode of The VitaDAO Aging Science Podcast, we delve into the intricate dance of time and biology with Dr. David Meyer and Prof. Sarah Voisin. As we broadcast from the vibrant atmosphere of the ARDD conference in Copenhagen, we engage in a thought-provoking dialogue about the ticking of the epigenetic clock and the adaptive changes that come with aging. Dr. Meyer, a bioinformatician with a penchant for genome stability, and Prof. Voisin, an expert at the crossroads of epigenetics and bioinformatics, share their insights on groundbreaking conference presentations and their own pioneering research. Together, we tackle the pressing issues of sustainability and overpopulation, pondering the role of longevity scientists in these global conversations. Listen in as we dissect stochastic changes during aging, discuss the impact of exercise on epigenetic aging, and consider the nuances of sex differences in biology. This episode is a must-listen for anyone curious about the future of personalized health interventions and the quest for a longer, healthier life.

In this episode of The VitaDAO Aging Science Podcast, we embark on a fascinating journey through the realms of longevity and cellular health with Dr. Arwen Gao. Dr. Gao, a leading authority in the fields of aging research, metabolism, and lysosomal pathways, takes us on a deep dive into the science behind extending lifespan. We'll explore the secrets of C. elegans, the tiny worm with big insights into human aging, and unravel the mysteries of the unfolded protein response (UPR). Join us as we navigate the complex landscape of scientific discovery, discussing the challenges and triumphs of studying aging, potential breakthroughs, and the future of healthspan. Whether you're a seasoned scientist or new to the world of longevity research, this episode offers a captivating glimpse into the world of aging and the possibilities it holds for a healthier, longer life.

What is decentralized science and what will be its impact on research and innovation? Joined by experts from Arcadia Science, VitaDAO, and the Foresight Institute, we discuss the challenges posed by traditional scientific models and the rise of alternative approaches. From new funding mechanisms to the transformative potential of AI, we explore the evolving landscape of research and the promise it holds for the future. Episode HighlightsDriven by a quest for faster breakthroughs, collaboration, and democratization, decentralized science is on the rise. It's a counter to traditional models—like tenure and strict lab hierarchies—that restrict autonomy and potentially dampen innovation.Are scientific advancements speeding up or stagnating? The insights reveal that there is no simple answer as there are questions about how we measure innovation itself.Through a diversity of new funding mechanisms through prizes, fellowships, or grants, there's a strong push to support bold projects that might be overlooked by traditional institutions.Arcadia Science merges open science with for-profit models to accelerate research and ensure swift dissemination of discoveries.VitaDAO harnesses blockchain for scientific governance, creating an inclusive and permissionless platform for collaborative research funding and exploration.Foresight champions frontier technologies, such as nanotechnology, fostering collaborations and offering diverse enabling platforms suited to each field's unique needs.What's Next?Seemay Chou emphasizes that in the future, the distinction between decentralized and centralized science may blur, as decentralized approaches become more common. Vincent Weisser highlights the increasing role of AI in scientific progress. He envisions a future where AI, particularly multimodal AI, becomes a significant driver of scientific discoveries. Allison Duettmann predicts that more countries worldwide may establish private and decentralized alternatives to traditional governmental funding for scientific research. Seemay Chou: LinkedIn, X/TwitterArcadia Science: Website, GitHub, LinkedIn, X/Twitter Vincent Weisser: Website, LinkedIn, X/TwitterVitaDAO: Website, LinkedIn, X/Twitter Allison Duettmann: LinkedIn, X/TwitterForesight Institute: Website, LinkedIn, X/Twitter Understanding science funding in tech, 2011-2021 by Nadia AsparouhovaEngines of Creation by Eric Drexler Austin Next Links: Website, X/Twitter, YouTube, LinkedIn

In this episode of The VitaDAO Aging Science Podcast, we delve into the world of age-related eye diseases with Prof. Dorota Skowronska-Krawczyk, a renowned expert in vision and aging. We explore fundamental aging mechanisms, challenges in research, and the potential of senolytics for eye conditions. Prof. Dorota shares insights into the retina's mysteries, the eye's unique immune status, and her groundbreaking work at UC Irvine. Join us as we uncover the intricate ties between vision, aging, and the future of eye health

In this enlightening episode of the Aging Science podcast, we dive deep with Prof. Vera Gorbunova, a trailblazer in the realm of longevity and aging research. Our discussion spans a myriad of fascinating topics, from the mysteries of genome stability and the unique biology of naked mole rats to the promising role of hyaluronan in cancer prevention. We explore the groundbreaking findings on SIRT6 activators like fucoidan, delve into the world of comparative transcriptomics, and unravel the enigma of Peto's paradox. Prof. Gorbunova's insights into DNA damage, its correlation with aging, and the potential therapeutic applications of her research are truly captivating. We also touch upon her recent project with VitaDAO and the potential future of aging therapies. Join us as we journey through the intricate tapestry of aging science, uncovering the secrets that could reshape our understanding of longevity.

In this episode, we delve into the world of DeSci, or Decentralized Science, which serves as a bridge between technologies like Synthetic Biology, Longevity, and Ethereum. DeSci aims to revolutionize the current scientific system, highlighting its flaws such as friction, corruption, and outdated practices. By utilizing blockchain technology, DeSci seeks to improve scientific institutions and processes. The conversation with pioneers Boris Dyakov and Mikey Fischer sheds light on the vast potential of DeSci and its ability to transform scientific progress. It goes beyond mere improvement, presenting a paradigm shift in the way science is conducted. The second conversation with Alok Tayi of VibeBio illustrates a fascinating use case for using DeSci to solve diseases that are underserved in TradSci. DeSci envisions open and modular scientific data, akin to the accessibility of financial tools in the blockchain world. Additionally, the emergence of DAOs in DeSci brings opportunities for capital allocation and funding clinical trials. Join us on this exploration of the frontier of Scientific Progress, where traditional and decentralized science collide. ------ Timestamps 0:00 Intro 1:30 Scientific Progress 5:30 BORIS & MIKEY 8:50 Overcoming TradSci 13:00 Open Science 16:25 VitaDAO 19:00 What is DeSci? 23:23 Bullish on Science 28:30 Onboarding Scientists 34:00 The New Infrastructure 35:00 AI and Science 43:00 ALOK TAYI 44:10 Vibe Bio 47:00 The Long Tail of Disease 52:00 Inflection Points 54:00 Solving Disease 59:45 The Power of DAOs 1:07:45 Governance and Structure 1:11:30 The Crypto Value Add 1:14:00 Regulation 1:19:00 A New Primitive ------ Resources Boris Dyakov https://twitter.com/BJ_Dyakov?s=20 Mikey Fischer https://twitter.com/0xMikeyF?s=20 Alok Tayi https://twitter.com/aloktayi?s=20 DeSci Ethereum Foundation https://ethereum.org/en/desci/ Gitcoin DeSci Fund https://bounties.gitcoin.co/grants/5105/the-decentralized-science-community-fund Vibe Bio https://www.vibebio.com/ ------ Not financial or tax advice. Bankless content is strictly educational and is not investment advice or a solicitation to buy or sell any assets or to make any financial decisions. This newsletter is not tax advice. Talk to your accountant. Do your own research. Disclosure. From time-to-time we may add links in this newsletter to products we use. We may receive commission if you make a purchase through one of these links. Additionally, the Bankless team hold crypto assets. See our investment disclosures here.

In this episode of the Aging Science podcast, we engage in a thought-provoking conversation with Prof. Joao Pedro De Magalhaes (@jpsenescence). Our dialogue covers a wide array of subjects, including the philosophical and scientific aspects of aging research, the potential of transhumanism, and the intriguing concept of cryonics. We delve into the repurposing of drugs for longevity, the phenomenon of inflammaging, and the promising potential of cellular reprogramming. We also discuss the challenges and opportunities in the field of aging research, the future of biogerontology, and the exciting developments in the Genomics of Ageing and Rejuvenation Lab.

In this episode of the Aging Science podcast, we delve into an insightful discussion with Dr. Heidi Pak (@pak_heidi). Our conversation spans various topics, such as the distinction between fasting and time-restricted feeding, the influence of caloric restriction on different mouse strains, sleep cycles, and the challenges of grad school. We also explore the healthspan vs lifespan debate, the future of nutritional recommendations, and the burgeoning field of circadian rhythms.

Laurence Ion is a Steward at VitaDAO - a community-owned collective dedicated to funding and advancing longevity science.Longevity is the defining question of the century. Laurence is passionate about health & longevity due to his personal experience struggling with disease.Laurence was one of the key organizers of Zuzalu, Vitalik Buterin's pop-up city in Montenegro, and worked with Niklas to put together new initiatives to break through the regulatory bottlenecks that hold back the science & technology of longevity.This episode encapsulates our thinking on the flawed ethical and regulatory paradigm in medical innovation, resulting from many months of problem analysis and solution-finding through conversations with governments and policymakers in Latin America, Africa and Europe.The future we want to build is one where we use a different regulatory paradigm, as safe or safer than the existing one, while faster to innovate. A safe haven for refugees of age-related diseases that want to try something different, rejuvenate and heal.Most importantly, Laurence and Niklas believe community-building is at the heart of what we do, and having seen the possibility of creating talent density like in Zuzalu inspires us to push the boundaries further, and build a bigger movement.A movement aligned in defeating the Dragon Tyrant of Aging.If you're a biotechnologist, renegade life scientist or relentless entrepreneur who wants to help radically supercharge human health and extend lifespan, join us!The key upcoming initiatives are:Longevity State Congress in Sep 2023Prospera Buildweeks 2023 starting in Oct 2023DeSci & Longevity Biotech 2023 - A Próspera Builders' Summit in Nov 2023Start a Longevity Network State in Latin America in Q1-2024

We all know it, even if we try our best not to dwell on it: one day, we will age and eventually die. Or will we?Sara engages in a conversation with Sebastian Brunemeier to explore the potential reversal of aging and the prospect of avoiding death. Sebastian Brunemeier is a General Partner at Healthspan Capital, a venture fund focused on longevity biotech and regenerative medicine. He is also CEO of ImmuneAGE Bio, a drug discovery platform for immune system rejuvenation. He was previously co-founder and CIO at Cambrian Biopharma, one of the largest longbio companies, Founder and COO of Samsara Therapeutics, a clinical-stage autophagy drug discovery company in Oxford UK, and Principal at Apollo Health Ventures, the largest aging-focused venture fund with 200M under management. He was a Fulbright Scholar on telomere biology, holds a master's degree in molecular neuroscience and biotech business management from the University of Amsterdam, and was in the PhD program on the biochemistry of aging at Oxford as a Clarendon scholar before dropping out to launch Cambrian. He is an advisor to several companies including VitaDAO, the longevity DAO00:00 Introduction01:35 Understanding the connection between aging and mortality07:26 The pursuit of biological immortality11:24 Strategies for prolonging life15:45 Promising areas of research in the field of longevity24:10 Exploring autophagy during fasting26:03 Sebastian's personal longevity regimen28:05 Overrated and underrated aspects of longevity research32:29 Gender disparities in longevity studies35:17 Contributing to longevity research efforts37:28 Web3 and its intersection with biotech42:00 Should we truly extend human lifespan? Examining the downsides and longevity dividends48:39 The Vitalism movement54:00 Societal transformations in a world without aging01:02:03 The impact of an extended lifespan on birth rates

This episode of the Rejuvenation Roundup Podcast features our Rejuvenation Roundup, as well as a Lifespan News video on AI and a Life Noggin video on overpopulation, as well as a video created in collaboration with our partners at VitaDAO. You can subscribe on your favorite podcasting platform. Learn more at lifespan.io/roundup 0:00 Intro 0:41 Hypoxia Extends Median Lifespan in Fast-Aging Mice by 50% (1) 2:33 A Senolytic Drug May Already Be in the Clinic (2) 4:13 AI Beats Humans in Answering Healthcare-Related Questions (3) 5:31 Using AI to Discover New Rapamycin-Like Molecules (4) 7:45 Lifespan News: 3 Ways GPT-4 Fixes Healthcare and Could Cure Aging (5) 11:33 Lifespan News Short: Arnold Schwarzenegger Wants to Live Forever (6) 12:32 Life Noggin: Overpopulation - Are We Too Late? (7) 15:58 VitaDAO - Funding The Future of Longevity Science I Crypto meets Longevity (8) Links: 1 - https://www.lifespan.io/news/hypoxia-extends-median-lifespan-in-fast-aging-mice-by-50/ 2 - https://www.lifespan.io/news/a-senolytic-drug-may-already-be-in-the-clinic/ 3 - https://www.lifespan.io/news/ai-beats-humans-in-answering-healthcare-related-questions/ 4 - https://www.lifespan.io/news/using-ai-to-discover-new-rapamycin-like-molecules/ 5 - https://youtu.be/BA7r_HGdZ9A 6 - https://www.youtube.com/shorts/v3VmWB0PiG4 7 - https://youtu.be/7VHaJYnaDhk 8 - https://youtu.be/LgEiYbIJVOY

This episode of the Rejuvenation Roundup Podcast features our Rejuvenation Roundup, as well as two Lifespan News Shorts and a Life Noggin video on depression. You can also subscribe on your favorite podcasting platform. Learn more at lifespan.io/roundup 0:00 Intro 0:38 Low Carb Intake Linked to Insulin Resistance (1) 2:22 Rapamycin Rescues Age-Impaired Blood Flow in Mice (2) 4:53 Sleep Quality and Duration Associated with Stroke (3) 7:54 Life Noggin: Are You Stuck in the Depression Loop? (4) 11:41 Lifespan News Short: "Young Gut" Microbiome Associated with Longevity (5) 12:49 Lifespan News Short: DNA Damage Repair No Longer a DREAM (6) Links: 1 - https://www.lifespan.io/news/low-carb-intake-linked-to-insulin-resistance/ 2 - https://www.lifespan.io/news/rapamycin-rescues-age-impaired-blood-flow-in-mice/ 3 - https://www.lifespan.io/news/sleep-quality-and-duration-associated-with-stroke/ 4 - https://youtu.be/XY5jYPta0uQ 5 - https://youtube.com/shorts/zUc-n254nw0 6 - https://youtube.com/shorts/h6DNxSwQ7YE

In this episode of the Aging Science podcast we talked with Prof. Nir Eynon (@nir_eynon). We touched on many topics, including elite athletes, how COVID affected working culture (for the better), the benefits of tabatas, epigenetic and muscle clocks and how they are affected by exercise, biases in research and the role of meta-analysis.

We had a marvelous conversation with Assoc. Prof. Viktor Korolchuk (@VIKorolchuk) about autophagy, mitochondria, senescence, the importance of modelling, and human desire for radical lifespan extension. Originally from Ukraine where he received his Ph.D., Viktor worked in Cambridge as a postdoctoral fellow and later moved to Newcastle upon Tyne in the beautiful north of the UK to pursue his work on aging. He has received a grant from VitaDAO to identify novel autophagy activators against aging and lysosomal storage disorders.https://www.vitadao.com/projects/korolchuk-lab

Slowing aging by a couple of percents would save more money than curing any single disease, be it cancer, heart disease, or diabetes. Aging is, in fact, the major risk factor that all these diseases have in common. For this reason, slowing aging becomes the most efficient path to a sustainable and healthy future for humanity. To get this message out we started The Aging Science podcast. We will bring you interviews and frank conversations with leading experts in the field of longevity, as well as evidence-based health advice to support you on this journey. This podcast is brought to you by VitaDAO and Kamil Pabis, MSc (the @Aging_Scientist on Twitter). In this podcast, I (@aging_scientist) had the pleasure of interviewing Asst. Prof Alaattin Kaya (@akay_lab). We talked about recent breakthroughs in the field, the difficulties of getting funding for risky and novel research, funding agencies, “fishing expeditions”, the importance of overexpression genetic screens in aging research, novel mechanisms of action, and the replication crisis.

In this podcast, I (@aging_scientist) spoke with Dr. Rich Miller about the ins and outs of mouse aging. The topics we discussed, roughly in this order, included the Interventions Testing Program, rapamycin, mecilizine, and other lifespan-extending drugs. We talked about the importance of genetically heterogenous mouse stocks and the issues with fast-aging progeroid mouse models. We also covered his more recent work on aging rate indicators and the difference between classic biomarkers and aging rate indicators. Finally, we talked about the importance of lifespan research, misuse of the word healthspan, and the emerging use of frailty indices in mice. VitaDAO and Kamil Pabis, MSc (the @Aging_Scientist on Twitter) bring this podcast to you.

Sebastian Brunemeier, Building Puerto Rico, Puerto Rico Money, ImmuneAGE Locations, Switzerland Benefits, Distributed Biotech, ChatGPT, vitaDAO, DAOs, Non-profit, Accredited Investors, Mental Energy, Ageism, Hopelessness, Downhill After 18, Psychometrics, Healthspan Capital, Mouse Bottleneck, Business Opportunity, Mouse Models, Synthetic Models, Age-related Diseases, Human vs Mice, Cloning, Reverse Yamanaka Factors, Progeria Cells, IP, Investing, Contracting Out, Matthew "Oki" O'Connor, Cyclarity, Cholesterol, Brain Aging, Bone Marrow Transplant, ImmuneAge Special Sauce, Competitors, Biobank, Missing Team Members, Books, Longevity Biotech Fellowship, The post Immune System Rejuvenation, Startups, & Investing – Sebastian Brunemeier -Learning with Lowell 175 first appeared on Learning with Lowell.

Today's blockchain and cryptocurrency news Bitcoin is down slightly at $27,952 Ethereum is up slightly% at $1,866 Binance Coin is up slightly at $312 Australian Securities and Investments Commission has cancelled Binance's derivatives license India ramps up CBDC onboarding efforts. Bitcoin White paper deep in MacOS system file. VitaDAO votes to create for-profit company. DWF labs injects $16M into RACA. Learn more about your ad choices. Visit megaphone.fm/adchoices

Drop 1: Twitter Pay https://cointelegraph.com/news/elon-musk-wants-twitter-payments-system-built-with-crypto-in-mind Drop 2: Hamilton Lane na Polygon https://polygon.technology/blog/hamilton-lanes-2-1-billion-fund-opens-to-individual-investors-on-polygon-via-securitize Drop 3: Threshold Bridge https://www.axios.com/2023/01/31/threshold-network-bitcoin-ethereum-bridge .. More: Decentralized storytelling StoryCo https://www.coindesk.com/web3/2023/01/26/hollywood-in-web3-storyco-raises-6m-to-decentralize-storytelling/ CryptoQueen Dra Ruja Ignatova reaparece em Londres https://www.bbc.co.uk/news/uk-england-london-64407723 FoxBit Pay para pessoas físicas https://valor-globo-com.cdn.ampproject.org/c/s/valor.globo.com/google/amp/empresas/criptomoedas/noticia/2023/01/27/foxbit-pay-podera-ser-usado-para-pagamentos-cripto-entre-pessoas-fisicas.ghtml Premier League NFTs on Sorare https://t.co/dAcLMTDPoU Pfizer Ventures lidera rodada de investimento na VitaDAO, DAo de DeSci https://www.moneytimes.com.br/pfizer-ventures-e-outras-vcs-investem-na-vitadao-organizacao-de-ciencia-descentralizada/ https://www.ledgerinsights.com/pfizer-vitadao-decentralized-science/ Metamask Learn https://learn.metamask.io/ Binance Mastercard crypto card no Brasil https://www.reuters.com/technology/mastercard-binance-launching-prepaid-card-brazil-2023-01-30/ ImmutableX wallet: Passport, to ease onboarding into web3 games https://www.coindesk.com/web3/2023/01/31/immutablex-to-launch-all-in-one-passport-solution-to-onboard-new-gamers-into-web3/ Broadridge: plataforma de repo alcança 1 Trilhão de USD em volume https://www.ledgerinsights.com/broadridges-dlt-repo-dlr-1-trillion/ Dispositivo sensorial trás tato para o metaverso https://www.designnews.com/vrar-hardware/skin-haptic-device-provides-true-touch-sensation-metaverse Smurfs lançam jogo web3 via Lens protocol https://mirror.xyz/0x48758c0EF34BF22a4aaA837bD9B323F26E4a1e1F/LkSx5G1wZ3Rrwa82vjPzetmMcNHI_2523cV5LBzJKg0 Paris Blockchain Week - web3 startup competition com Google Cloud https://www.intelligenthq.com/paris-blockchain-week-and-google-cloud-launch-web3-startup-competition-reaching-100-plus-innovative-founders/ Austrália pública taxonomía crypto, dividida em 4 tipos https://cointelegraph.com/news/australia-introduces-crypto-assets-classification/ eBay se junta a NFTplazas para lançar colecionáveis dos esportes https://nftplazas-com.cdn.ampproject.org/c/s/nftplazas.com/ebay-notable-live/amp/ .. Meu conteúdo em inglês https://bi.11fs.com/ Me sigam em blockdrops.lens --- Send in a voice message: https://anchor.fm/blockdropspodcast/message

Large language models generate functional protein sequences across diverse familieshttps://twitter.com/jermdemo/status/1619214824185147392?s=46&t=BnRBgAZ-NwFelhA49dKknwPfizer Invests $4.1 Million In Decentralized Science Organization VitaDAO Fundraising Roundhttps://thedalesreport.com/trends/pfizer-invests-4-1-million-in-decentralized-science-organization-vitadao-fundraising-round/Prisms VR raises $12.5M to improve math literacy with virtual realityhttps://venturebeat.com/games/prisms-vr-raises-12-5m-to-improve-math-literacy-with-virtual-reality/Meta is inexplicably shutting down one of the best Oculus gameshttps://www.theverge.com/2023/1/31/23580356/meta-shut-down-echo-vr-oculus-quest-arena-ready-at-downRumor: HP will finish VR related production by the end of the yearhttps://twitter.com/SadlyItsBradley/status/1620729001152237569?s=20&t=4LKuZnzOtX9tXp4LfGoETQ

Nueva semana, nuevo episodio, nuevo resumen. Este un poco mas corto que los anteriores porque no pasaron muchas cosas esta semana, tengo que prepararme alguna seccion para casos de emergencia. Mi Twitter: @lodelascryptos Comunidad de Telegram: https://t.me/+RKIkAKeKmS5iY2Nk Fuentes: Cryptofolio: https://t.me/CryptoFolioES/1253 https://www.theblock.co/post/206552/pfizer-ventures-backs-decentralized-science-startup-in-4-1-million-round https://www.reuters.com/technology/mastercard-binance-launching-prepaid-card-brazil-2023-01-30/ https://www.coindesk.com/web3/2023/01/30/premier-league-inks-deal-with-digital-trading-card-platform-sorare/ https://brave.com/january-wallet-partners/ https://tokeninsight.com/en/news/opensea-to-introduce-3-hour-hold-period-to-mitigate-theft-related-risk https://www.coindesk.com/policy/2023/02/03/india-reveals-imf-is-working-with-g-20-for-crypto-regulations/ https://www.diariobitcoin.com/nft/actor-anthony-hopkins-compone-musica-en-piano-para-los-titulares-de-sus-nft/ https://www.diariobitcoin.com/ethereum/zhejiang-disponible-full-capacidad-7-febrero/ https://www.diariobitcoin.com/paises/asia/rusia/gigante-banco-rusia-sber-estrenara-plataforma-defi-ethereum/ https://www.diariobitcoin.com/nft/ebay-busca-contratar-personal-en-nft-y-web3/ Keywords: Podcast, podcast de criptomonedas, Sorare, MasterCard, Brasil, Binance, VitaDao, Pfizer, DeFi, Socios.com, Ethereum, Bitcoin, Ebay, NFT, Rusia.

Welcome to Blockcast! Here's the crypto news for the week: 02:31: Bondee Unmasked 12:26: D&D Fans Assemble To Take On Capitalism 20:32: Bright Future Ahead for VitaDAO as Pfizer joins with $4.1Million? Follow our socials for more content and updates! Instagram: https://bit.ly/3VGfoRX TikTok: https://bit.ly/3X0LsRE Youtube: https://bit.ly/3WPpcuj Telegram: https://bit.ly/3vzRdtS Website: https://thefinancialcoconut.com/ Check out our other shows: https://bit.ly/3Zb6rTS Disclaimer: The content in Blockcast is solely for education and entertainment purposes. It does not serve as any form of advice or recommendations. -- Blockcast is the brainchild of web3-focused news platform Blockhead and The Financial Coconut. Highlighting the latest in blockchain and web3 in Southeast Asia and beyond, there's nothing cryptic about this brand new crypto podcast. From NFT nuances to institutional implications, Blockcast brings you weekly bite-size TLDRs and ICYMI discussions of the industry. -- The Financial Coconut started out as a reaction to online fake gurus propagating over simplified get rich quick programmes & a desire to share best practices revolving around personal finance which has since turned into a network of content championing the idea of creating a life you love while managing your finances well. Hosted on Acast. See acast.com/privacy for more information.

幻冬舎の暗号資産（仮想通貨）/ブロックチェーンなどweb3領域の専門メディア「あたらしい経済 https://www.neweconomy.jp/ 」がおくる、Podcast番組です。 ○解説したニュース ・Oasysのトークン「OAS」、ビットバンクへ上場決定 ・カゴメ、ブロックチェーン活用の「日本の野菜で健康応援債」発行へ、みずほのPFで ・ツイッター、決済機能導入に向けライセンス申請、暗号資産取り扱いも視野＝報道 ・「TOEIC Program」公開テスト公式認定書にブロックチェーン証明、サイバーリンクス ・アバランチ（AVAX）、エクスプローラーアップグレードでPチェーン可視化向上 ・バイナンスとマスターカード、ブラジルで暗号資産カード提供へ、南米2カ国目 ・長寿研究の「VitaDAO」、製薬大手ファイザーらから約5.3億円資金調達 ・NFTサッカーゲーム「Sorare」、英プレミアリーグと提携 ・YGG Japanがプライベートラウンドで約4億円調達、スクエニ・セガ・グリーなど18社より ・NEARとウォレットアプリ「Ledger Live」統合 ・ゴム先物取引の受渡決済にブロックチェーン、日本証券クリアリング機構 ○番組スポンサー この番組はFiNANCiEの提供でお送ります。 ・株式会社フィナンシェ 「FiNANCiE（フィナンシェ）」は、スポーツチームやエンタメプロジェクト、DAOなどのトークンを購入して支援ができる新しいクラウドファンディング・サービス。サッカーJリーグ、野球、バスケ、などのプロスポーツチームをはじめ、映画やアイドル、インフルエンサーなど100以上のプロジェクトのトークンがフィナンシェで購入できます。さらにトークン購入者はプロジェクトに応じたキャンペーン参加やNFTなどの特典も。ぜひiOSやAndroidで「FiNANCiE」のスマホアプリを入れて、新たな応援体験を味わってください。「あなたの夢が、みんなの財産になる」FiNANCiE →App Store（対応OS：iOS 12.0以上）はこちら https://apps.apple.com/jp/app/financie/id1470196162 →Google Play（対応OS：Android 6.0以上）はこちら https://play.google.com/store/apps/details?id=jp.financie.ichiba ○関連リンク ニュースの詳細や、アーカイブやその他の記事はこちらから www.neweconomy.jp/

Today's blockchain and cryptocurrency news Bitcoin is down slightly at $23,102 Ethereum is down .5% at $1,579 Binance Coin is down slightly at $307 NYDFS investigates Gemini Philippines securities exchange regulator seeks comments from the public Premier league partners with Sorare Arbitum based DEX emerges from stealth. Hypernative picks up $9M in a seed round. Pfizer Ventures backs VitaDAO. Learn more about your ad choices. Visit megaphone.fm/adchoices

Many independently minded, young scientists are too ambitious for academia… But the startup world isn't quite right for them either. How might decentralized science provide a space for these innovators to do their work? Niklas Rindtorff is the classical scientist behind LabDAO, an online home for inventors that builds open tools for scientific research. Niklas coauthored his first paper before the age of 20, and he has expertise in CRISPR and cancer research. On this episode of Boost VC, Niklas joins us to explain how classical science emerged after World War II and explore the problems with the NIH grant funding process. Niklas shares his open-access approach to consuming scientific media and describes how DeSci is experimenting with different ways to measures the importance of new science. Listen in to understand how decentralized science can serve as the bridge between research organizations and science startups, building an ecosystem for inventors who don't fit into the nonprofit or for-profit world. Topics Covered How Niklas defines scienceFormal knowledge generation processFishing at edge of what is known How World War II changed the way we do scienceConflict won because of US sophisticated techNIH funding created class of full-time scientistsSystem doesn't always maximize progress How the importance of new science is determinedMeasured by citations vs. marketsDeSci experiments with different accounting How Niklas consumes scientific mediaUsed to use few free, open-access journalsNow leverage Twitter bookmarks, preprints What LabDAO does for scientistsProvide tools to work wherever they areCurrent focus on computational biology What inspired Niklas to build LabDAOExperience with inventions stuck in bureaucracyMeasure number of patients treated vs. citations The age distribution of NIH grant recipientsAges with scientists who were firstNo market discipline, don't answer to public How we might equalize the demographic of NIH winnersCreate more NIHsPrivate funding agency with philanthropic match How we might invest in a portfolio of scienceCharge higher fee to run research-oriented fundOnline collectives do research sponsorships How LabDAO itself is fundedNonprofit governed by tokenPrivate investors buy token for stake on projects The relationship between academia and DeSciConnective tissue among existing organizationsInventors who don't fit in academia or startups Niklas' definition of successStrive toward personal valuesInvent cool stuff Connect with Niklas RIndtorff LabDAO https://www.labdao.xyz/LabDAO on Discord https://discord.com/invite/labdaoLabDAO on GitHub https://github.com/labdaoLabDAO on Snapshot https://snapshot.org/#/labdao.ethLabDAO on Medium https://medium.com/@labdaoLabDAO on Twitter https://twitter.com/lab_daoNiklas on Twitter https://twitter.com/niklas_tr   Resources Broad Institute https://www.broadinstitute.org/‘Science the Endless Frontier' 1945 Report to Congress https://www.nsf.gov/od/lpa/nsf50/vbush1945.htmNational Institutes of Health https://www.nih.gov/Public Library of Science https://plos.org/bioRxiv https://www.biorxiv.org/New Science https://newscience.org/VitaDAO https://www.vitadao.com/ Connect with Boost VC Boost VC Website https://www.boost.vc/Boost VC on Facebook https://www.facebook.com/boostvc/Boost VC on Twitter https://twitter.com/BoostVCBoost VC on Instagram https://www.instagram.com/boost_vc/

Niklas speaks with Sebastian A. Brunemeier.Sebastian is the Co-Founder and General Partner at Healthspan Capital, a venture fund focused on longevity biotech ("LongBio") & geroscience.He is also the Co-Founder and CEO at ImmuneAGE Pharma, a drug discovery platform for immune system rejuvenation.He holds an advisor and board member position at multiple companies and organizations, such as VitaDAO and Molecule AG.This episode is recorded as a primer to the "Prospera Healthtech Summit 2022", a conference taking place September 23-25 on the island of Roatan, Honduras.Sebastian talks about the scientific breakthroughs of the past decades that show the path to end or at least significantly slow human aging.What remains is an engineering challenge.What follows is a wide-ranging conversation about the regulatory, policy, and business challenges when it comes to producing scientific innovations in the field of geroscience to result in drugs and therapies to treat humans.Sebastian argues that the mainstream legal and financial guardrails of the medical system are broken, and instead we need alternative guardrails built on-chain.Sebastian and the longevity movement are building these alternative guardrails such as decentralized science (de-sci) funding, decentralized autonomous organizations (DAOs), and intellectual property (IP) on non-fungible tokens (NFTs).Sounds science-fiction? It is already science-fact. LongBio has attracted close to $1bn in funding in recent years.Sebastian introduces us to this emerging ecosystem that develops the powers to unleash a new wave of human progress through better health and longer age.We close the episode by talking about network states, and how Puerto Rico is creating the perfect conditions for a longevity hub.Niklas on Twitter: https://twitter.com/NiklasAnzingerInfinita Fund Website: https://infinitafund.com/Discord: https://discord.gg/Z4H6UjbubK

Niklas Rindtorff is a Physician-Scientist and one of the Pioneers in decentralised healthcare and life sciences. He has an MD from Heidelberg University and he received his Master's Degree in Biomedical Informatics from Harvard Medical School as a Fulbright Scholar. He is a founder of LabDAO, an online community of life scientists collaborating to increase the accessibility of life science tools both in the dry lab and wet lab. He's also a Core Member of VitaDAO, a collective funding early stage longevity research. DAOs are Decentralised Autonomous Organisations and a staple of the ongoing WEB3 revolution. Investopedia defines DAOs as having no central governing body, every member within a DAO typically shares a common goal and attempts to act in the best interest of the entity. Popularized through cryptocurrency enthusiasts and blockchain technology, DAOs are used to make decisions in a bottom-up management approach. Or as Niklas describes them, DAOs are basically a WhatsApp group chat with an attached cryptocurrency bank account. In this conversation, I find out about how DAOs can be used in healthcare. From enabling rare disease research to fixing science's publishing problems. I hope you enjoy. You can find me on Twitter @MustafaSultan and subscribe to my newsletter on www.musty.io

In Episode 53, we're thrilled to be joined by Savva Kerdemelidis and Nicholas Fiorenza from Crowd Funded Cures, a web3 project with a mission to launch a DeSci crowdfunding platform to incentivise the discovery of new uses for off-patent drugs, plant medicines, nutraceuticals and other unmonopolisable therapies without reliance on patents by using IP-NFTs, Pay-for-Success (PFS) contracts, and the issue of Public Good Medical Prize NFTs. Sound complicated? Don't worry, they do a great job of breaking it down in this episode as we discuss the role web3 can play in funding medical research and development, IPNFTs, and the amazing potential in the DeSci movement.Five Key TakeawaysDeSci provides new opportunities to engage individuals and communities in scientific research and development, and to create a more collaborative and open-source space.IPNFTs allow for the fractionalization of ownership in early-stage biopharma projects and research, providing greater access to liquidity for researchers.Pay-for-success models help incentivize research into new uses for off-patent medicines without the traditional risks.IP NFTs and pay-for-success models will allow for greater research into medicines and therapies that have traditionally been ignored due to a lack of profitability.Blockchain alone won't solve the issues plaguing scientific research and development, but it will make solving them a lot easier.Follow and learn moreFollow Savva on TwitterFollow Nick on TwitterCrowd Funded Cures TwitterWebsiteDiscordMediumRedditEpisode Time Stamps02:17 -  What was your “Ah hah” moment that originally got you interested in cryptocurrency and web3?05:11 - Give me a high-level overview of Crowdfunded Cures, and how it all got started10:12 - What are public good medicines, and why did you choose this as your area of focus?12:34 - As part of your platform, you are planning to make use of IP-NFTs and a Pay-for-success model to fund research and testing – tell me more about this.17:39 - I understand that you are looking to potentially restructure CFC as a DAO in the future. Tell me about the roadmap for this.22:10 – How do you reconcile decentralization and medical research, which is traditionally highly centralized?27:05 - What is the long-term vision for Crowdfunded Cures?30:31 - I understand that you are partnership in the works with VitaDAO, and potential NFT collections, tell me more.36:21 - DeSci is a relatively new movement that aims to disrupt how scientific research and development takes place. What do you think the DeSci movement will look like 5-10 years in the future?Buy us a coffee!Enjoy the episode? Help us out by buying us a coffee:Fiat - https://www.buymeacoffee.com/cryptoaltruismSupport us with a small Crypto DonationETH(ERC20) - 0xac5C0105914F3afb363699996C9914f193aeDD4AOther tokens: cryptoaltruism.org/supportusDISCLAIMERWhile we may discuss specific projects or cryptocurrencies in this podcast, please don't take any of this as investment advice, and please make sure to do your own research on any potential investment opportunities. Full disclaimer available HERE.

On this week's episode of Campfire, Jackson talks with Laurence Ion and Theo Beutel from VitaDAO, a DAO democratically funding longevity research. So far, they have deployed over 2 million dollars over 10+ projects with the help of their community. Gather around to hear about the current state of science research, VitaDAO's value proposition, their working groups, and governance structure. Topics Covered: What is Longevity? — (01:55) The State of Traditional Science Research — (04:02) What is VitaDAO? — (06:10) Laurence and Theo's Roles at VItaDAO — (10:58)Applying for Funds From VitaDAO  — (15:45) IP Within a DAO — (18:38)VitaDAO's Partnerships— (19:50)How Proposals to VitaDAO Work —  (22:40)Repurposing Ideas — (23:55) VitaDAO's Governance and Token — (26:00)VitaDAO's Projects — (31:50)VitaDAO Funding its Community — (34:45) Want to learn more about what new technologies are waiting to be released? Follow us on Twitter or join our Discord to find out what's in store for us and how we make use of Web3 in both digital and physical space. See you at the next Campfire

On today's episode of Translating Aging, Chris welcomes Tyler Golato and Laurence Ion to talk about VitaDAO, a collective accelerating research in human longevity and decentralized drug development.  The pair start the conversation off by discussing their company's roots -  a previous business venture that sought to change the incentive structures around drug development.  VitaDAO was created as a means to support biological longevity research through decentralized means.   They go on to discuss VitaDAO's future, how they can increase liquidity, and their goals to advance drug development.  Golato and Ion argue that the present is a perfect time to create VitaDAO, given the current intersection between biotech, block chain, and longevity research.  They conclude by recalling the early-life dreams that inspired them to enter this field.  Episode Highlights: The essence of VitaDAO Changing the incentive structures around drug development The partners' passion for longevity VitaDAO's decentralized structure  Project sourcing and funding Increasing liquidity Goals to end drug development The intersection of biotech, block chain, and longevity Why Tyler and Laurence are interested in longevity Quotes:  “VitaDAO was born out of an early concept that we had been working on at a company called Molecule, which is a company that I co-founded about three years ago with a vision of doing decentralized drug development.” “It's not completely open, completely decentralized to the point where it's paralyzing for the organization, but we try to look at the things that are most valuable to decentralize in order to make the organization as maximally efficient as possible.” “We really try to make it as easy as possible for token holders to make informed decisions about whether or not something is ultimately worth funding. We like to do so once we're at the point where we ensure that we can actually progress with a deal.” “We are distinctly different from a venture fund in terms of our endpoint is not really ROI impact, it's really impact in the space. And that comes in many different forms, in terms of taking a diversified approach to funding longevity research.” “Even if we spin out a NewCo, these contributors can vote on what projects are funded, how they are spun out, and then they can co-invest and help these therapeutics eventually come to market.” “In the long term, we really hope to be able to do a lot of things within the decentralized science ecosystem as the space broadens and has liquidity to do so through partnerships with organizations like Molecule and LabDAO.” “Certain things like clinical trials don't yet have a business model. So we can create one by having either philanthropic groups, patient groups or even a government/life insurance company that has an economic incentive to improve health outcomes.” “Crypto has long been dismissed by the incumbents.” “People who are really looking at how technology and innovation can drive humanity forward and drive the way that we govern.” “What problem is more interesting than human aging? I mean, for me, it's so philosophical; it's so poetic.” Links: Email questions, comments, and feedback to podcast@bioagelabs.com Translating Aging on Twitter:https://twitter.com/BioAgePodcast ( @bioagepodcast) BIOAGE Labs Websitehttps://bioagelabs.com/ ( BIOAGELabs.com) BIOAGE Labs Twitterhttps://twitter.com/bioagelabs?lang=en ( @bioagelabs) BIOAGE Labshttps://www.linkedin.com/company/bioage-labs/ ( LinkedIn) https://www.vitadao.com/ (VitaDAO Homepage)

My guest today is Paul Kohlhaas who is the founder of Molocule as well as a member of VitaDAO and PsyDAO. Molecule is a decentralized biotech protocol that is democratizing biopharma research and development This one is going to blow your mind. We chat: How drug development current works The monopolistic nature of drug development The Open Source pharma movement Longevity research DAOs Psychedelics medicine DAOs How the Molecule team is building the future of Decentrlzied Science This episode offers a rare sneak peek into the future of medicine Please enjoy my conversation with Paul https://twitter.com/paulkhls https://twitter.com/molecule_dao https://twitter.com/vita_dao

It started with a tweet. A 25 year old woman named Mallory was suffering from an infection that had failed all antibiotic treatments. A researcher named Dr. Steffanie Strathdee was using Twitter to hunt for the impossible - a scientist somewhere in the world who might have the right phage - a virus that infects bacteria - that could save this patient. When Jessica Sacher (a phage researcher) showed her friend Jan Zheng (a UI/UX developer) the tweet, the idea for Phage Directory was born. A simple, elegant solution to a global problem. Phage Directory started as a list of phage researchers and a newsletter called Capsid & Tail. To date, it has facilitated multiple phage cures, grown a global community of researchers who hold potential treatments for future drug-resistant infections, and built a model for discovery research from benchtop to bedside, N-of-1 cures. Jan and Jessica are making the leap to Australia to further their mission with Phage Directory and help build a safety net on a country-wide scale for these types of infections. Get inspired by the progress that Jan, Jessica, and their research community has made for cures of drug-resistant infections through a global, decentralized network of researchers.This is an UltraRare x VitaDAO collaborative podcast. Thank you for listening.Website: https://phage.directory/Guest Twitter:https://twitter.com/JessicaSacherhttps://twitter.com/yawnxyzJessica Sacher BLOGhttps://jessbio.substack.com/Hosted by Jocelynn Pearlhttps://twitter.com/JocelynnPearlVitaDAO is the world's first decentralized intellectual property collective, funding and commissioning research into human longevity. Participate in the VitaDAO community! ⇛ Website : https://www.vitadao.com/⇛ Discord: https://discord.gg/vitadao⇛ Telegram: https://t.me/vitadao⇛ Twitter: https://twitter.com/vita_daoTimestamps00:00 Intro.1:07 Intro of Phage Directory co-founders2:13 How the idea of Phage Directory came about? (Jessica Sacher)4:57 Background and experience in tech (Jan Zheng)8:40 The first successes with Phage Directory12:04 How does the alert to cure process look like?16:20 The bottlenecks in the process18:58 The process of putting together Phage Directory23:41 Community onboarding29:40 How is Phage Directory monetized?33:28 The business model of Phage Directory35:13 Why is Australia a good place for phage Directory?40:28 Phage Directory strategy43:15 Ways to access the information about the Phage Directory process44:50 The relationship between the co-founders46:17 Web 3 space and Phage Directory53:00 The options of becoming a DAO54:14 The vision for Phage Directory for the next 5 to 10 years1:03:00 Ways to support the mission1:04:56 How big is the network?1:07:00 How to get involved and be part of the community?1:11:25 Closing

Speakers: Prof. Dr. Björn Schumacher, Prof. Jan Gruber - National University of Singapore, Prof. Eugene Berezikov Host: Max Unfried

In this episode of Voices of the Data Economy, we spoke to Paul Kohlhaas, co-founder of Molecule Protocol and coauthor of VitaDAO.  VitaDAO is a community-owned collective funding early-stage longevity research. Paul Kohlhaas is an entrepreneur and economist with a passion for open-source utility networks. A passion for pharmaceutical innovation led him to found Molecule, a networked marketplace that enables the distributed R&D and funding of new chemical intellectual property. In a chat with us, he spoke about the need for longevity research, IP-NFTs, DeSci, and more. Below are edited excerpts of the episode. Voices of the Data Economy is supported by Ocean Protocol Foundation. Ocean is kickstarting a Data Economy by breaking down data silos and equalizing access to data for all. This episode was hosted by Diksha Dutta and audio engineering is by Saurabh Singh. --- Send in a voice message: https://anchor.fm/dataeconomy/message

This episode brings you into conversation with Ben Hills (0xboodle) and Darren Zhu to talk about how the principles of the web3 movement might give scientific publishing a much-needed upgrade. Co-hosted by Jocelynn Pearl (UltraRare, Lady Scientist Podcast) and Vincent Weisser (VitaDAO), we dive into the thinking behind what Darren and Ben have written about this space. We hope it inspires future discussions and progress in this field. This is an UltraRare x VitaDAO collaborative podcast. Thank you for listening.Articles mentioned: Tokenized Thought by 0xboodle: https://0xboodle.substack.com/p/token...Magna Carta Scientia by Darren Zhu: https://atoms.org/scientiae#smart-res...Find our guests here:Darren https://twitter.com/atoms_orgBen https://twitter.com/0xboodleVincent https://twitter.com/vincentweisserJocelynn https://twitter.com/JocelynnPearl#blockchain #desci #web3 #daoSubscribe wherever you listen to podcasts:https://podcasts.apple.com/us/podcast...https://open.spotify.com/show/624VxO4...

We're bringing you into conversation with Niklas Rindtorff and Arye Lipman, two of the leaders behind LabDAO (https://www.labdao.com/). Hosted by Jocelynn Pearl, we dive into the ideas behind LabDAO and what the team hopes to accomplish with this decentralized endeavor. Future UltraRare x VitaDAO collaborative episodes will feature conversations at the intersection of science and web3. Connect with these communities here:LabDAO Discord: https://discord.com/invite/labdaoVitaDAO Discord: https://discord.com/invite/vitadaoFind our guests here:Niklas https://twitter.com/Niklas_TRArye https://twitter.com/aryelipmanJocelynn https://twitter.com/JocelynnPearl#blockchain #desci #web3 #dao_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _VitaDAO is the world's first decentralized intellectual property collective, funding and commissioning research into human longevity. Participate in the VitaDAO community! ⇛ Website : https://www.vitadao.com/ ⇛ Discord: https://discord.com/invite/3S3ftnmZYD ⇛ Telegram: https://t.me/vitadao ⇛ Twitter: https://twitter.com/vita_dao

今回もYoursDAOコミュニティでDAOを紹介してくれているタカラ君と共に注目のDAOをご紹介していきます。 ご紹介したDAOはこちら！ 1.MadRealitiesDAO( https://www.yoursdao.xyz/posts/madrealities-dao ) 恋愛リアリティショーの所有権を分割で持って演出に意見を言えるDAO 2.Friends with Benefits( https://www.yoursdao.xyz/posts/friends-with-benefits ) 最近キンジョウがトークンを購入してジョインしたソーシャルコミュニティの代表格FWBについて 3.VitaDAO( https://www.yoursdao.xyz/posts/vitadao ) 2人で共通で盛り上がって最も注目の分散型科学について（DeSci:Decentralized Science） パーソナリティ3人のtwitterはこちら！お気軽にご質問をどうぞ。 中司：https://twitter.com/nakatsukasa_13 金城：https://twitter.com/illshin タカラ：https://twitter.com/kiz77_eth YoursDAOコミュニティに入って一緒にDAOのデータベースプラットフォームである https://www.yoursdao.xyz/ を作りませんか？ YoursDAO：https://discord.gg/QQAuWqnhU8 Twitter：https://twitter.com/yoursdao

VitaDAO Discussion Panel - On the quest to quantify biological age Host: Max Unfried Speakers: Dr. Morgan Levine, Nikolina Lauc, Dr. Joris Deleen

Na ons alles verteld te hebben over Opgavegericht werken in een eerdere podcast, is onze goede vriend Gidion Peters opnieuw te gast om ons meer te leren over een relatief nieuw fenomeen dat de wereld van organisaties soms volledig op zijn kop zet: Decentrale Autonome Organisaties, waarmee het idee gezamenlijk ondernemen een compleet nieuwe invulling krijgt, en een opzet die mede mogelijk gemaakt wordt door nieuwe technieken als Blockchain.  Dus doe mee en probeer samen met ons te bevatten wat deze hele andere manier van organiseren voor jou en de wereld kan betekenen. Nieuwsgierig naar een aantal zaken die we besproken hebben? Hier vind je meer informatie: Astrodao, een platform om zelf DAOs te starten: https://astrodao.com/ CityDAO, de eerste DAO stad / gemeente: https://www.citydao.io/ VitaDAO waar samengewerkt wordt aan levensverlengende therapie: https://www.vitadao.com/  De grootste DAO's van dit moment vind je op https://deepdao.io/#/deepdao/dashboard  En wil je meer lezen over DAO's, check dan ook Gidion's artikel hier: https://www.organizeagile.nl/update/wat-is-een-dao-de-organisatievorm-die-grenzeloos-samenwerken-mogelijk-maakt/  Wil je onze podcast steunen? Wordt dan Patron van onze podcast voor maar een paar euro per maand via onze Patreon pagina.  Daarnaast horen we uiteraard graag van jullie, stuur daarvoor een appje via WhatsApp, of bel ons gewoon op 06-12701281 (Roel) of 06-17376146 (Just) of contacteer ons via LinkedIn (Roel of Just)

A conversation with the VitaDAO core team. VitaDAO is a decentralized autonomous organization — or DAO — that focuses on enabling and funding longevity research. The sketch of how a DAO works is that people buy voting tokens that live on top of the Etherium blockchain and then use those tokens to vote on various action proposals for VitaDAO to take. This voting-based system contrasts with the more traditional model of a company that is a creation of law or contact, raises capital by selling equity or acquiring debt, and is run by an executive team who are responsible to a board of directors. Since technically nobody runs VitaDAO the way a CEO runs a company, I wanted to try to embrace the distributed nature and talk to many of the core team at once. This was definitely an experiment! The members of the core team in the conversation in no particular order: Tyler Golato Paul Kohlhaas Vincent Weisser Tim Peterson Niklas Rindtorff Laurence Ion Links VitaDAO Home Page An explanation of what a DAO is Molecule Automated Transcript VitaDAO [00:00:35]  In This conversation. I talked to a big chunk of the VitaDAO core team. VitaDAO is a decentralized autonomous organization or Dao that focuses on enabling and funding. Longevity research. We get into the details in the podcast, but a sketch of how a DAO works is that people buy voting tokens that live on top of the Ethereum blockchain.  And then they use those tokens to vote on [00:01:35] various action proposals for me to doubt to take. This voting based system contrasts with more traditional models of the company. That is a creation of law or contract raises capital by selling equity or acquiring debt, and is run by an executive team who are responsible to a board of directors.  Since technically, nobody runs for you to doubt the way it CEO runs the company. I wanted to try to embrace the distributed nature and talk to many of the core team at once. This was definitely experiment. Uh, I think it's your day. Well, Oh, well, but I realize it can be hard to tell voices apart on a podcast.  So I'll put a link to a video version. In the show notes. So without further ado, here's my conversation with Vita Dao.  What I want to do so that listeners can put a voice to a name is I want to go around everybody say your name and then you say how you would pronounce the word VI T a D a O. Tim, would you say your name and then, and then pronounce the word that [00:02:35] that's kind of how I've done it. Yeah. And so I'm the longevity steward we can help kind of figure out deal flow on, edited out, so. Awesome. All right, Tyler, you're next on. It is definitively Vieta Dell. Yeah. And I also help out with the longevity steward group. I started starting longevity group and I'm the chief scientific officer and co-founder at molecule as well. And then Nicholas you're next on my screen. It's definitely beats it out. And I'm also a member of the longevity working group in this science communication group and also currently initiating and laptop. Great. And then Vinson. Yeah. So it's the same pronunciation weeded out, but I'm helping on the side and also on kind of like special projects, like this incline where that I took around, we had recently and yeah, in Lawrence. Lauren Sajjan Vieta thou. And I [00:03:35] also steward the deal flow group within the longevity working group. And I think we should all now say as a hive mind, Paul Paul has said at the same time, oh, sorry. I'm going to say bye to dad. Mess with her in yeah. Hi everyone. My name is Paul cohost. I would say, be to down. I actually wonder what demographics says, Vida, like RESA. We should actually look into that. It's interest, interesting community metric. I'm the CEO and co-founder of molecule and one of the co-authors of the VW. I also work very deeply on the economic side and then essentially help finalize deal structures. So essentially the funding deals that we've been carry through into molecule and yeah, very excited to be here today. And maybe we can jump back into Lawrence adjusted  we well, [00:04:35] also, so the thing that's confusing to me is that I always assumed that the Vith came from the word vitality. Right. And so that's, that's where the idea of calling it a fight Vita doubt, right? Because like, I don't say vitality, I say fighting. In German, it's actually retaliatory. Yeah. So it's just like the stupid Anglo centrism that is from the Latin, I would say from the word life. Yeah. Cool. So to really sort of jump right in, I think there's the, to like, be very direct, like, can we like walk through the mechanics of how the, how, how everything actually works? Right. So I think listeners are probably familiar with sort of like the high level abstract concept of there's a bunch of people. They have tokens, they vote on deals you give researchers money to, to do work, but like, sort of [00:05:35] like very, very mechanical. How does the dowel work? Could you like walk us through maybe like, sort of a a core loop of, of like what, what you do Yeah. So I mean, the core goal of the DAO is really to try and democratize access to decision-making funding and governance of longevity therapeutics. And so mechanically, there's a few different things going on and anyone feel free to interrupt me or jump in as well. But, so I would start from the base layer is really having this broad community of decentralized token holders, which are ultimately providing governance functions to this community. And the community's goal is to deploy funding that it's raised into early stage. Clinical proof of concept stage longevity therapeutics projects. And these basically fall between these two, let's say points where some tension exists in when it comes to translating academic science. So you have this robust early stage, let's say basic research funding mechanism through things like the NIH [00:06:35] grant funding, essentially. And that gets really to the point of being able to do, let's say very early stage drug discovery. And there's also some sort of downstream ecosystem consisting of venture capital company builders, political companies that does let's say late stage funding and incubation of ideas. They're more well-vetted, but between there's this sort of problem where a lot of innovation gets lost, it's known as the translational valley of death. Yeah. What did we try to do is we try to identify as a community academics that are working and let's say, have stumbled onto a potentially promising drug, but aren't really at the point yet where they can create a startup company. And what we want to do is basically by working together as a community, provide them the funding, the resources, in some cases, even the incubation functions to be able to do a series of killer experiments, really deep risk of project, and then file intellectual property, which in exchange for the funding, the dowel actually, and this is, this is sort of mechanically enabled by a legal primitive that we've been developing a molecule called an IP [00:07:35] NFP framework, which basically consists on one side of a legal contract, typically in the form of a sponsored research search agreement between a funder and a party that would be receiving the funding, the laboratory, and on the other side of federated data storage layer. And so the way this works is basically beat a doubt would receive applications. Some of these projects could, for example, be listed on molecules marketplace have an IPN T created meta dealt with would send funds via the system to the university and in exchange, they would hold this license and essence for the IP, that results from that project. And then within the community, we have domain experts. For example, we have a longevity working group which consists of MDs. Post-docs PhD is basically anyone that has deep domain experience in the longevity space. They work to evaluate projects due diligence and ultimately serve as sort of a quality control filter for the community, which consists of non-experts as well. Maybe just people who are enthusiastic about what. And beyond that, there's also additional domain expertise in the [00:08:35] form of some people who have worked at biotech VCs, for example, people with entrepreneurial experience and through this community, you basically try to form, let's say a broad range of expertise that can then coach the research or work with them and really help the academic move the IP and the research project towards the stage where, where it can be commercialized. And now VitaDAO stewarding this process. They have ownership in the IP and basically what would happen is if that research has out license co-developed sold onto another party, just made productive in essence and. It's successful in commercializing those efforts and received some funds, let's say from the commercialization of that asset, that goes back into the treasury and is continuously deployed into longevity research. So the long-term goal is to really create this sort of self-sustaining circular funding mechanism to continue to fund longevity research over time. And now within that, we could wrap it all into, you know, there's a bunch of like specific mechanics in there. I would love to, to rabbit hole, [00:09:35] I think Vincent, yes, to and on the kind of very simple technical layer, kind of very initially we started off just having this idea and putting it out there and then like having like a kind of Genesis auction where everyone could contribute funds. Like some people contribute 200 bucks and others contributed millions. And in exchange for that. Just like as a, there is an example, like for every dollar they gave, they gave, got one vote in organization. And then this initial group of people that came together to put, to, to pool their resources, to fund longevity, research, got votes and exchange, and actually with these votes, basically they can then what Tyler described make on the, on these proposals that that are vetted through the longevity working group, they can make a vote if it shouldn't get funding. And, and that's of course kind of like the traditional, like model of like a Dow and of like token based governance and boating [00:10:35] and yeah, which we did of course was like kind of like a very easy mechanism that got it started, but then the storm of course can also be useful for different purposes and can also incentive. People working on specific projects, research has also getting told and so kind of getting a governance, right. And organization in exchange for good and contributing work. Nicholas, did I see your hand? Yes. And maybe one thing to add here that takes a bit of a step back. It's adding, adding the question. Why does all of this matter? Why does the style framework Adderall fall? And I think when you, when you look at the way currently academic research works, basically the incentives for the scientists and the moment that something is published in a peer reviewed journal, so that the system is optimized for peer review publication. And then on the other hand, on the translational side, when something, you know,[00:11:35]  Turning into a medicine return on investment. And they're basically calculating a risk adjusted net present value of the project. Now, the problem with a lot of biomedical research is the science has, is done. The paper is published, but a risk adjusted present value of the project is still approaching zero because there there's still some key experiments are missing or to get that experiment off the ground. And actually this is where the doubt can come in and using new technologies to basically financialize the IP and make it more liquid. And may, maybe more specifically the asset isn't created, you know, a lot of research you know, the NIH has not focused on therapies. I mean, not the creation of new therapies where value is actually created. They'll, they'll do clinical trials on existing therapies, but, but you know, the real value inflection points are not done through basic basic research. So, so that's where we hope to solve. Got it. So, [00:12:35] w I think in my, in my mind, the thing that's really interesting about Vieta Dow, as opposed to other dads is, is the sort of like interface with the, with the world of atoms that that's like a pretty, pretty unique and exciting thing. So there's, there's, there's a lot of mechanics there that I'm actually interested in digging into. So like one thing is in order. So, so sort of all, in order to. Give money to a researcher even at some point they need to turn it into dollars or euros in order to buy the equipment that they need to, to do the research. And so are they, they're like taking the, VitaDAO token and then converting that into, into currency. How does, how does that work? Yeah, I can speak to this or Paul or if you want to, if you want to speak to it. So, I mean, I can, I can maybe kick it off. So one of the things that's really important and that we've been really focused on at molecule is ensuring that the process of working with researchers, which goes [00:13:35] well beyond just working with the research, right? You need to work with the university, with the tech transfer office. You need to negotiate a licensing agreement and all of this can happen in a way that is somewhat seamless and it doesn't require them. Let's say having to do all of their interactions with it, let's say a. You know, this sort of ephemeral entity that exists on the Ethereum blockchain. So we've basically created rails by a molecule for things like Fiat forwarding we're negotiations with the TPO for a lot of the legal structures to ensure that it's as smooth as possible, the Vino tokens themselves don't actually play into. We can, we can give those to researchers as an incentive and to people who perform work for the community. But that is not actually the, what is, what is given to researchers. Researchers. When, when a proposal is passed within the community, we have a certain treasury and ether, for example, that we've raised over over a period of time that is liquidated and sold for USD decency. And then that USB-C travels via off rails that molecule has created to ensure that the university [00:14:35] can just receive beyond currency. So I mean, a big part of this. Know, defy in a lot of ways has some advantages in that. It never has to really interact with real world banking systems. This is a challenge in the D space. We still have to interface with tech transfer offices. We still have to, you know, speak to general counsel at universities and make sure that people are comfortable working this sort of way. And I would say this is probably one of the most significant challenges and the reason that, you know, a lot of legal engineering and a lot of thinking went into how to create the base layer infrastructure that allows us to actually operate in this space. So it's, yeah, it's a challenge. It's something that we're always trying to iterate on. I mean, we imagine a future where universities do have wallets. You know what I mean, researchers do have wallets, but it's going to take some time for that future to be realized. And in the midterm, I think it's really important to show the world. The dowels can work effectively, especially these types of dowels that have a core mission, vision of funding research. They can do that productively even given the constraints of the, of the current. And [00:15:35] so that, so, so like negotiating with tech transfer offices like they, I assume need to sign a sort of an analog legal agreement with a analog legal entity. Is that correct? And is that, is that like, is molecule that, that legal entity or like, how does, how does that work? Yeah, so maybe so to reiterate what Tyler said, there's actually nothing stopping that say from a university to directly engage with a doubt. I think it's more that those systems don't exist it, and there's not enough, like precedents to kind of enable those. There's also much larger, for example, question of like, to what extent could it litigate against the patent and actually actually enable, enable this protection. And so if you did operates through a set of different agents so these are analog, real wealth legal partners, and some molecule is one of those legal partners in essence. So we can, we can ensure that we are the licensing party, for example, with a tech transfer office. And then we enter into a sub licensing agreement, for [00:16:35] example, with with B to them. And in the same sense as what were tologist explained, we also then ensure that all of the, the, the payment flows and the. Are compliant to Kahn systems, something that we've realized it's, it's, it's really important to kind of bridge this emerging with three world with the real world to really make it as seamless as possible. And not for example, for us that yeah. University to go through the process of opening a Coinbase account figure out what is USB-C actually. But I mean, fundamentally I I like to use this analogy. If you can make an international EFG with like a big number and a swift number, like actually crypto is much easier than that by now, but it's a much less much less adopted system, even from an accounting perspective. Accounting for funding flows in, in this decentralized system is very simple. Like the, the proof of funds is very easy to provide because you can visually see where every single transaction can be traced back to. But so the way that we've tried to design really the flow of funding within. With Nvidia down within molecules to make it as seamless and [00:17:35] interoperable with the real well today as possible. And also to ensure that we have the highest degree of legal standards, legal integrity. So we work with with specialized IP counsel and IP law firms across the world in different jurisdictions to really ensure also that any IP that we adopt funds and that is encapsulated within these IP NFTE frameworks is future-proof. Because that, that's something that became very apparent for us. When we, when you work with IP, you can't really, you can't really make mistakes in terms of how you protect the intellectual property. And you also have a responsibility to actually the therapeutics that are being developed there, because if you, if anything was to invalidate the IP that could fundamentally influence whether a potential therapeutic can actually ever reach patients. Yeah. And so I think that the, the, the one. The question is there has to be a lot of trust between the Dow itself and sort of the, the organization or [00:18:35] people doing the negotiation and sort of holding the IP and forcing the IP. Because, because there's like at that sort of Dow analog interface there's is my impression is that there's no like enforceable legal contract. Right. So is that correct? I'm just, I'm just trying to like wrap my head around, like the actual. It is an enforceable legal contract, actually. So the initial agreement between let's say molecule and the university is a typical stock standard sponsored research agreement that you would do at sea, between between two parties, like a pharmaceutical company and a university, for example. So these are, these are the same agreements that the universities use. In many case, we plug into their pre-existing templates. Those typically have within them an assignment agreement or an ability to sub-license where the company or whomever is doing this initial licensing then has [00:19:35] the right to license exclusively the, the resulting intellectual property, or in some cases, even the full rights of the agreement molecule now engages in. Fully contractual, fully enforceable, typically in the context of Switzerland where the company is based agreement sublicensing agreement with the Dow via the election by via the election of this agent process. And now, so I would say the weakest part of that, if you want to think about where the sort of core let's say. Yeah, like the breaking points are with in that process would be, would be around the fact that there is required a large amount of trust in the agents, but really what the agent is doing is, is actually putting themselves at risk. They're taking on legal liability in some cases on behalf of the dowel. And so. Something if that Peyton was, let's say that agent made offer something or wasn't able to honor their agreement. I mean, there is full legal recourse that it could be, that [00:20:35] could be taken. But this is, yeah. Again, when you look at Peyton enforceability and Indian electoral property landscape, most of these things like, you know, you find out what works through, through litigation. These things have not been litigated yet. There's not really precedent for enforcement here. But this is also what it takes to innovate in the intellectual property landscapes. So it's, there is a tension between these things, but it, yeah, maybe to your original question, there's a lot of, is a lot of trust, certainly involved in I'm thinking about when we go, we go stuff is that there's like no first principles of it. It's just sort of like poke it and see what happens. Yeah, maybe as an interesting, it will be interesting case studies before it becomes relevant to us because in the space, kind of like some of the core protocols, like units open curve, I actually governed by dolls now. And actually they are now enforcing the IP actually at the courts. So even before it will be come necessary for us, there will be cases and case studies of kind of like it's very big organizations like a human 12 or [00:21:35] curve enforcing and going through the courts like this, even this year or next year already cases that are coming up. So it will be really interesting to see what are the legal precedents or like a Dow and forces is yeah. IP through agents basically. And I think there will be precedent before we will have to kind of in false our IP. Yeah. Well, it's literally saying your name. Well, one thing to add there. So to reiterate what Vincent said as well, I mean, that was a very quickly become powerful economic agents. And I think enforcing enforcing let's say processes in our legal system is often a function of capital. So I think if you did that, for example, was to ever get to a point where it had to enforce one of its one of its IP cases. It would definitely have the financial backing to do so, and it can operate through agents to kind of enforce the validity of its IP. And then the remaining processes that's, that's considered like the relationships between agents are really [00:22:35] subject to the same legal processes that we have today. When two companies enter a entered equilibrium, and if a biotech company enters a sponsored research agreement with the university, the trust agreements that are set up there are, are, are not different. And, and the underlying legal contracts that we using are also the same, I think. Back to Vincent's point, there are actually first cases where Dows are enforcing their IP. This is in the context of fits in ICU, open source software development, where, where a dowel let's say has developed a certain protocol, but that protocol is open source. But it's probably running under a specific software license and the Dow is not choosing to actively enforce its its IP against someone who infringed against that license. I think one additional aspect here is to when we think through trust and where is trust, concentrated and power concentrated from the Dow is to note that that, although there are these agents that are available for a Dodge interact with the real world, the capital's [00:23:35] concentrated within the network of token holders. And, you know, just on a technical level, there's this multisignature wallet that holds all the funds and that's controlled by members of the community. And it's all basically in a token gated way. And that network structure, that social network, which is basically the Dow, I think can be very well compared also to some kind of association where you have people all across the world, collaborating, they're all aligned by, by a token incentive to pursue one shared mission. And then the Dow the network. Start agreements with various agents. So it's not really relying on one particular agent fulfill its mission. If there was a situation which trust or agreement with one individual real-world agent know w would be broken, then still most of the capital wise with the Dow and the Dow would have the ability to engage in a D and an agreement with a different entity. It's not like there's one entity or one vulnerability. When, when you think [00:24:35] through the contact zone between the digital Dow and the physical company, and speaking of agents at what level does the entire membership of the Dow folk, right? Like, are they, are they voting on every decision? Like we want this person as our lawyer, we want this person. Yeah. Yeah. Now basically to make it kind of concrete there's like, of course, like a core team and stewards who actively working and we'll also have of course some yeah, for example, on the, on the longevity side, helping to solve steel flow, doing all of these activities, and then it's mostly on the bigger funding decisions, for example, should we fund this project with automation dollars, but it won't be on, should we hire this designer that will be like autonomy, for example, with the. The design team to hire a designer and budgets that are basically voted through. So it's not, micro-managing kind of in depth sense, but it [00:25:35] kind of more the key overall big decisions, what the community was able to do. So, I mean, early in the, in the community's formation and in the Dallas formation, there was a governance framework that basically laid out a series of, of, of decisions as to how governance actually functions in the doll. And there's in B doll, there's this sort of three tier governance system moving from conversation that is quite stream of consciousness oriented in discord, moving to semi formalized proposals for community input in a governance framework called discourse. And then ultimately. Things that make it past that stage, moving onto this sort of software platform for a token bass boat. And part of that governance framework that was initially created, also invested a certain amount of decision making power within working groups and also set thresholds on what those working groups were able to spend, what sort of budgets they had and where they needed permission from the community ultimately to make decisions. So there might be. No for decisions greater than $2,500. That requires a [00:26:35] soft phone for things more than $50,000 requires a token days vote. And this is really important because as you can imagine, early on the organization, it can be super chaotic and really, really unproductive if every single decision that that was making needs to have this sort of laborious community-wide boat. But this is also a really interesting sort of iterative experiment, but I think many dollars are participating at the moment, which is really trying to figure out to what extent you can involve the community in a productive way in the sort of day-to-day operation. What's differentiates, differentiates a token holder from a contributor, from a core team member, from a working group member. How do people sort of move along that funnel and traverse those sort of worlds in a way where you get the most productive sort of organization? And this is something that is, I would say, being iterated on and improved constantly based on, you know, the, the sort of dialogue happening between the team and. And actually on that note, I have one vaguely silly question, which is why are all Dow's run on? [00:27:35] This is, this is, this is my, my, my biggest, my biggest complaint is I, I cannot pay attention to like streaming walls of text. Yeah. So it's like, how did, how did that emerge? Like, has anybody done a, a doubt, like, just run on like a forum or by email or something? Yeah, it is actually the biggest bag holder in most DAOs that operates. I'm just kidding. Actually. It's it's of course almost like mimetic it's like, that's how, like a lot of crypto projects, even like three, four years ago began to organize. And I think it's, it's ultimately, it's just the tooling. Like they were like slack and discord, this court to coordinate, and this court was much better in like enabling to participate in a lot of different channels very easily. But we're going to be, I think it's a lot about like, even like file sharing. All of these things you need, which go beyond. But ultimately there are kind of like some leading doubts that emerge just as a telegram chat between [00:28:35] five friends. And that I know like the leading, like art collected, I was like, please, it doubt. And that was just like five friends on a telegram or something. So of course you can envision like every possible way and model. Ultimately, I think it's, it's more like a, became a pattern that like a lot of projects organized food like this. Yeah. And I think there's also this like feedback thing that occurs with like the more people that are organizing by a discord in the early days, the more that people started to create like token integrations and token gating and things like snapshot and all of these sort of things where now there's like, because of that, a bunch of tooling from an integration perspective, that is, that is now developed, that makes it easier to operate in a community like that than it would be to have a slack channel, for example. Yeah. The best part, there is a serious lock-in effect. If you start your new Dow, the best choice is to go with discord because that's where all the other books, we, you know, folks that are already active plus you can leverage a lot of bots to allow you to token gate access or [00:29:35] send notifications, similar things. And another question is how did you all become the core team? Just show up Tyler and Paul probably could start telling them. I think maybe one interesting thing is that ultimately like every journey is kind of individually, but ultimately most people are just like saw very initially or like at a similar idea and kind of, it's almost, I think like, like a shelling point where like like also like, like I literally tried to register longevity doubt just the domain two years ago, before we, even before I met anyone who wasn't a Dow. And, and so I think there's like, and I think it's a similar story, even for Tim that, and then ultimately of course, there's like some mechanism of discovering it and, or like hearing him about the idea or meeting, like, ultimately for me, it was meeting Tyler and Paul because of molecule and then for a lot of people, actually, they just saw an interview. They saw [00:30:35] an article about it, jumped into discord, introduced themselves, for example said, yeah, we would love to help on the website. I would love to help on the view flow and then started helping and ultimately through that mechanism. And I think like, People like bubble it up basically, and just started writing an article or doing a low or, but then became more and more integrated parts of most kind of like, like work themselves into it. And also of course, like like a lot of people have never met each other in person or is it like, and, but it kind of like this, this trust I think emerges and builds up doing like just engaging and helping progress the Dow as a whole. But I think it's, it's actually really interesting, exciting to see kind of like just this like global coordination emerging out of like the shared purpose or mission. And a lot of people just stepping up and like initially we didn't have a token, we had $0 and they were like people who like spend weeks, we building a website pro bono without [00:31:35] expecting anything like re like really good research has joining me into this. Before we even had like $1 funding to give towards research. So I think it would have to, yeah, that's kind of also the inspiring part. I think about a lot of dialysis that it just naturally emerged and everyone can do this a bit of like no boundaries, but then yeah, self-selected almost,  On Nicholas raising his hand was going to give him a chance to say something, right? Yeah. So I think there's the saying, I've read a couple of days ago that some ideas are occur in multiple different brains at the same time. And I think that's really what also happens if we, to Dow Vincent let's think about this for some time. Lawrence had basically stopped developing mobile applications, really figured, you know, focused on aging research, Paul and Tyler thought about this topic. Marketplace for ideas, intellectual property. Tim had been, I think, thinking about this idea and, you know, basically crop funding, academic, or just fundamental research as a community for some [00:32:35] time. And I've been sufficiently frustrated with the way academia currently works and have been actually also thinking about, okay, can there be some kind of mechanism where a community bootstraps itself into existence and funds, scientists and entrepreneurs within its community. Everybody pays a little and then you can actually allocate a lot to the really good ideas. And in some ways I think, you know, we all have some kind of predecessor to this idea. And then when we each had these individual time points heard about it, there was just a, who was a very intuitive decision to join. I think it's like a certain amount of serendipity, a certain amount of like Twitter network effects, like a weird variety of things. Like you know, we started out with like just like white paper and an idea. And then, you know, through, through that, got in touch with a couple of different people, but then people just start showing up. I mean, weird. The most interesting thing for me about the Dow experiment is like early on, we had like this [00:33:35] sort of like, okay, people want to be working with group members. This is like pre doubt. Not even like Vincent saying no token yet, nothing trying to figure out, like, how do you organize this community? How do you do something meaningful? We were like trying to collect applications or something. And then it's like, some people would apply and we're like academy, who's going to be good or whatever one person who's now the lead of the, of the tech working group, this guy, Audi Sheridan applied and was rejected, but then just like made himself super valuable. Like he started doing things that were like, no one else could do. Became an invaluable member of the community. And then we sort of realized like, why are we doing this application thing? Like people just show up there's things that need to be done. Sometimes we don't even see what those things are. People have good ideas, they make proposals. And all the sudden, you know, you, it's not like a company where there's a hiring process. There's very little, you can, anyone can show up on the discord tomorrow, identify some pain points, make a proposal, and just demonstrate to all these other people [00:34:35] that they have value to add to the community. And then, you know, there's, there's a sort of process there, but that process is, is still very loose. So I mean, most people who are here even on this call showed up through some like, like Nicholas and Vince were saying, I had been thinking about this before. We're sort of attracted to this magnet that is now a selling point for crypto in longevity and just had really great ideas about how to improve the community and elevated. And that's sort of, that's sort of, for me, the magic, I mean, You know, six months old now, roughly, I guess it'll be about six months and you know, the community is like 3,500 people or so, and, you know, hundreds of researchers, you know, dozens of people who are contributing pretty often, I don't mean some people full time at this point. And that's like a, a growth cycle to go from like a white paper and nothing to, you know, a bunch of money to fund R and D a bunch of intellectual capital you know, pretty strong political force in that amount of time would be [00:35:35] unprecedented. I think, for, for a company, especially something that's like bootstrapping from a community, not raising money from didn't raise money from BCS or anything like that. Just like had an auction for a token. It's to me, this is really interesting, and it sort of proves that, like, in terms of organizing intellectual capital and monetary capital, it's a really, really powerful mechanism. And so sort of related to the company point, or are you, are you worried about the sec. I mean, a huge amount of thought has gone into like the legal structuring and middle engineering and the dowel. So, I mean, the way it basically works is that the intellectual property that the Dao holds in the form of B's IP NFTs are not owned by the token holders. The token holders can sort of govern them by proxy through this governance, token and dividends are not paid out either. So the idea is to create, you know, it's not a nonprofit organization and the. As an organization is trying to make profit to further fund longevity research, but those dividends don't flow to, to token holders. [00:36:35] So there's not, you know, it's, it's, there's several prongs of the Howey test that are essentially being broken under, you know, whether it's things like making profits from the efforts of others and the fact that no one in the organization is directly profiting from, from sort of commercialization efforts the Dow is doing. But yeah, I mean, this is something, you know, thinking about the interaction between the Dow and the sec or, or, you know, like securities concerns played a pretty big role in the design thinking around the entire organization, the structure, because, you know, you can also go different routes. You know, some security token route or, or, you know, this, if you go these sort of routes, you really end up just excluding huge numbers of people from, from participating. So the goal here was like, how do you maximize participation in a way that is still ultimately creating value, but not necessarily creating value? You know, it's plumbed individual token holders, but really for the field of longevity as a whole and to move the needle on research. Got it. [00:37:35] So maybe, maybe to add a couple of points here. So the way that Vita token is fundamentally designed as a governance and utility token and at its highest level, you can think of it as something that is actively used by all members to curate the IP and the projects that they want to fund. And something that taught us that earlier is this, this very strong with typical let's say security, security, like assets, you have direct low dividends. You have very clear expectation of profits. In this case, first of all, you need to actively do something to be a member of VitaDAO and to then actively help to curate the IP. And the rights that come with it be don't token. There's no way that you could like say, okay guys, I'm out. And I want to take my share of IP that I helped create with me, which is also typical thing that you might have. You could have this as a shareholder, or if you're kind of in like more like a limited liability partnership type setting. So in this case, the Dao owns the IP and there's also, no, VDX not any expectations of profits that you could have because first of [00:38:35] all the goal here is to fund, to fund research, and really open up that research and then to try and make it accessible for the wealth which could actually mean open sourcing the research or open-sourcing the IP thus killing its commercial value. So that's a beat that discovered some. And it deem that discovery to be so important that it had to be open sourced and, and made accessible and thus they could never become a patient of all therapeutic down the line. Token holders have full rights to do that. Whereas I think if you, if you had a typical setting where you had a company and it was the whole, the shareholders and those shareholders had a very clear expectation of profits that would never fly in most normal companies. And so because there is no direct expectation of any, any potential returns that are made, there's not even the potential for return per se. And then there's that there's the full of governance option to essentially not commercialize anything. Yeah. Yeah, that's really cool. And actually sort of not quite related, but so, so I, I would say that that therapeutics. [00:39:35] Sort of a very special case in the sense of it's like very IP based there's, there's sort of very much a, like a one-to-one correlation between IP and product and those products can be very lucrative. So, so that's sort of why, you know, the therapeutics as, as an industry work. Do you think that the, the sort of the beat Dow approach could work for research and development outside of the therapeutic world? I guess as you're maybe, maybe rephrase your question, Ben is, yeah. It's just like, I guess the question is, is like the sort of idea that you can create incredibly valuable IP that like. It's fairly unique to the world of therapeutics and in many other sort of technological domains th the value really comes from like building the company around some IP and IP is [00:40:35] not that important. So yeah who wants to go for it? Go for Tyler. No, I was just gonna say quickly. So, I mean, I think absolutely because it also, it doesn't doubt doesn't need to be also IP centric, for example, Bita doc and have the holding data that was being produced by something. And that data could have intrinsic value. Similarly, meted out could try to get involved in manufacturing or create products. I mean, there's many different design flavors for these dowels. And I think the governance framework around this, and let's say the organizational capacity and the coordination capacity can be applied to many different problems in many different industries. And I think even the intellectual property thing does hold true well beyond therapeutics. So with therapeutics, you're right. They're very, very expensive to develop, which is why you tend to get this enforceable monopoly to try and basically incentivize people, developing them, but in textiles or engineering or, you know, [00:41:35] any sort of field where. IP plays a role. You could even apply almost a one for one one-to-one sort of model here, but beyond that there's many different flavors of assets and that sentence that adult could hold the other than probably most excited by is really things like data, which I think can be really, really powerful or software, which could be similarly powerful. And then, which I think a lot of dowels are already, already doing. For example, maybe it also has as one point also in addition to like, even like activities, like funding I P directly and kind of like having like a self fulfilling or like also you know, sustainable funding cycle there. We also, for example, had like these efforts that are completely philanthropic, if you like, and just helping to use also our community and to, for example, put together like this donation round on longevity and like exploring kinetic donations, like basically where, like I also like this idea even like before Kind of be the Dow existed.[00:42:35]  And I was like, okay, now we're like, kind of, there's like enough people and enough attention to do this. And the doll basically donated $65,000. But then for example, we literally donated 400,000 and we helped curate a projects which are all purely philanthropic, which are like open source projects, different even like, like NGOs doing like different projects and and basically helped also get our community together to donate to these different projects. And then talking a little bit for me, it's like, like one example where it's like really powerful because you have this like shining point of like crypto people were interested to fund longevity and they're not just interested to fund IP and FTS in a sustainable loop, but also to explore other funding experiments or other experiments. Like what another one we were discussing is like a longevity prize or like grants and fellowships for young people entering the field. All of that is actually kind of like advancing the whole cause and the whole community [00:43:35] and, and, and the core focus and activity of funding, IP, because with growth, our community and, and yeah, the whole field. So I think that's kind of actually an interesting point is that we are not limited to kind of funding IP, but it's of course, one of the core mechanisms we're engaging in. Yeah. I would add that there's also value in the community itself. Imagine Bitcoin, right? Anyone can fork it Instagram it's, it's a simple app. Anyone could have made a copy, but there's most of the value there and the net there that gets built. So here we have a team, right? The stellar team and the Dow itself is ultimately our R D. Awesome organization here. It got born in a Genesis by itself. It's a smart contract. So it's sort of unique in that way of it. Of course, someone interacted with the smart contract. It can be someone anonymous, but it issued 10% of his tokens, which by the way are [00:44:35] 64 million which is we're on 64 million, which is about the lifespan in minutes of the longest lived person, John Como. And that's sort of Beaky right. We can only extend that if someone lives longer than that, but anyone could buy those tokens, right? It's a fair auction including us, including random people. And then there was a vote to empower a core team like us. Yes, some of it, most of us here got involved before. But the cool part is anyone can start showing up and contributing a lot of value and ultimately the community can decide to do make them a core contributor to make them a steward of even some other efforts, right. Even something that we haven't thought about. There's always room it's permissionless. That's, that's something special definitely a metal experiment right here. And it's an experiment of sort of organizing people towards a common goal and a different way to make experiments, scientific experiments and, and figure out how to advance the therapeutics. We need to extend our healthy. You would actually be [00:45:35] curious. If I could ask you a question, Ben, on, on your thinking on, on poverty, how do you think, like, something like that fit into your thinking on just like new institutions for funding science, because you also mentioned this, like, it could also be a model of course, like we're potentially exploring it all. It's four different areas. And ultimately for me, it's like, if there's like big of enough of a community that is interested to fund something, like, like one of course, very like public example could be something like climate change or something exciting, like space. They would probably be at some point a community that would form resources and community to fund those research areas. It would be curious to hear from you, like kind of yeah. How you think for you to dial in the framework that you're outlining there. Like you're listening to the work? No really well with like pop up on this theme, you're exploring. Yeah. I mean, frankly, the reason I, one of the reasons I wanted to have this conversation was to sort of form those thoughts. So I [00:46:35] will be able to answer that much better after sort of like going after this. Right. So I think the, so just some of the tricky pieces, I think outside the domain of longevity is like longevity is, is very, you know, exciting to a lot of people with money both in the crypto community and outside of it. And so I think that's, you know, it's like, there's, there's lots of people who are excited about space, but from my experience, space, geeks tend to not be that wealthy. And so, so there's a question of just like you can, you can have a very excited community, but I think the real thing is like how much are those people really willing to put their money where their excitement is? That that's, that's a big question. Another question is, is for me that I think about it is like coordination around research. So, so I think another sort of great thing about therapeutics is that you really can, there's sort of like this nice, like one-to-one to one where you can have one [00:47:35] lab develop one therapeutic, which corresponds to one piece of IP, which corresponds to one product. And obviously it doesn't always work that way, but that's, that's sort of like a pretty strong paradigm, whereas with a lot of other technology it's. Sort of that, that attribution chain is very hard to do and it involves lots of different groups contributing different things. And so, and you need someone coordinating them. So this is, this is a lot to say. I think that there's very much something here. That's why I'm interested in it and why a lot more people to learn about it and why we're talking about this. But I, I think it's, it, it w it needs a lot of thought as is. It's not sort of like, I, I don't think that you could like, literally take what you all have done and just like, copy paste it for, for other domains. But that isn't to say that. Modify it and do something. Cause you know I think it's actually really, really pretty. Yeah. I mean maybe if I can speak on that [00:48:35] quick. So I think Dow will be a highly use case specific. It's actually been an interesting site. I've been I've I started writing about thousand mid 2016, 2016. There was an article that I wrote on like, what would happen if we combined let's say AI conscious AI systems with Adar. So kind of having adapt, having operated by autonomous agents in essence. And so what happened after the Dow launched, which was one of the first dollars on Ethereum? It was, it was a big complex autonomous kind of setup where the Dow was almost entirely just controlled through through dot holders. But then that also enabled a. An attack vector that essentially allowed someone to hack those core contracts. And then kind of the Dallas space went into a long period of of considering whether something like this should ever be attempted again. And people became, began to variously, very cautiously build out these systems. And there were, there's a couple of projects that over really over five years already have tried to build like generalizable Bal frameworks. And many of those projects have kind of have [00:49:35] you have failed that it actually providing frameworks that really got to mass adoption. And I think w whoever, someone, when, when you start building a down, it's kind of like, when you say, like, I want to build a company and there's many ways to build companies. And the difficult thing is not incorporating the Delaware or getting the bank account set up. And that's what sometimes people think today when they set up a doubt that like, oh, okay, it's a multisig, it's a discourse. But you obviously need that entire ecosystem that you're building. You need to think about, like, what is the, what is the value creation model for this style? What's its, what's its unique value proposition based on a value proposition, what type of community do I want to build? What type of culture do I need to implement that value proposition that will attract that community to help me? So we've needed that. For example, we've been very conscious about the type of open community that we wanted to build. And then this goes into all sorts of follow on questions. It's like, where do you actually get funding from to do what you do? And based on where that funding comes from, that will influence the culture of the community. For example, if you have a Dow that's funded by [00:50:35] several groups of larger VCs, that thou will be very different from a cultural perspective. And also from its goal is then a down that is funded by an open. Where now the individual members are much more, let's say engaged because they put some of their funding in. So they want to have a say on how to control it and what it gets used for. It's going to be very interesting to see, I think in the coming years, if, if generalizable frameworks and register, like just press a button and like spin up it, that you can already do that. There's many systems that do that, but I keep being surprised that like, they're actually not being very actively used. I think what is really important for example is to build basic infrastructure that can serve industries. And so, for example, if this is something that we we've been very focused on a molecule like drug development, isn't that different, whether you're saying you're developing longevity therapeutics or counts of therapeutics like the base kind of the base infrastructure and how you interact with the real world, for example, through IPS the same We kind of realized like decentralized drug development through Dallas, for example, could only really work if that was not a way to own IP. And then, but now I think for example, I [00:51:35] think a community like meta down will be very different than let's say a Dow that's focused on rare diseases where you're working with several patient advocacy groups. And it's not like there's a huge general excitement, unfortunately about diseases that are, that only affect small patient populations. Whereas aging affects affects all of us. And now the data that we're currently, for example, building out at molecule is called SIDA which will be a Dao that's focused on exploring and essentially democratizing access to psychedelics and mental health. Again, because we feel this is a topic that has a very broad appeal and where we can, where you can very effectively scale culture and also apply and also apply some of the frameworks ta-da. Yeah, maybe just one other thing. I think it's important to highlight in terms of how we think about this as well. Like the reason that dowels are interesting, even for me, like the reason that crypto is interesting is because it's effectively just a sandbox environment to try experiments that create behavioral outcomes like token engineering and token economics is [00:52:35] simply a way to motivate certain outcomes and certain behaviors in real time, sort of building and production, texting and production and academia. If I said, I want to change drug development, I want to change the way that pharmaceutical companies behave. I could probably write a paper in like nature reviews, drug discovery, and maybe kick off a policy discussion that ultimately isn't really going to move the needle at least on like a tangible timeline around how these things get solved. But what's interesting about those is that you can basically say I have this idea. There's the stakeholders that I want to incentivize to behave a certain way and achieve a certain outcome. And you can just like deploy this with software and start doing it. It's really crazy. I mean, the, one of the most interesting comments that Vitalik said, we hosted this topic. comment that resonated was that like, he felt the biggest sort of gift to humanity that corporate provided was this sandbox environment for experiments. And I think [00:53:35] as a scientist, this is one of the things that, that really, really strongly resonates. It's like move beyond the theoretical and go directly to the apply and start testing things in production, seeing what works. And I don't think we can say confidently that like dolls are biotech dolls. They're better than biotech companies. And achieving goals and drug development. But I think in a couple of years, we'll have a bunch of data points to suggest the things that Dallas are really good at, at least with this design implementation we'll know what they aren't good at. And because the organizations are so flexible and because they operate through this very iterative governance model that you have the ability to always be tweaking and always be improving. And so this for me is what's really, really exciting. It's like this crazy experiment that you're doing pulling in people from all over the world, independent of geography, geography. Like I haven't, if there was another tool kit to do it, that was an on crypto. We probably would have built it using that like it's. And, but really that the point here is. I haven't seen a better way to [00:54:35] scale incentives to a large group of people. Then we went three and crypto. So to me, this is, this is the most, yeah, I think we're done when it comes down to the point of the rights before that ultimately it's about a community, even with sidearm, like there's no token, there's nothing. We literally just set up like a telegram chat, invited some interesting people. They self selected themselves into now. It's like 500 people. We hosted like meetups and there's like ideas emerging out of all the people. And ultimately it doesn't really matter like how it's almost implemented or if there's a token, but it was like, what does community is to share the values and the culture of it and like, Like a shared mission also. So I think that's really, for me also, what's interesting to takeaway is that also looking at like the most successful projects in crypto has probably been projects like Bitcoin and Ethereum and, and I think a big part of the team success was its community and its culture persevering through thick and thin, like building and improving the protocol [00:55:35] together, building on it, being incentivized to build on it. I think that's like, like a major takeaway is that it would've made it. It's like all about communities and yeah, shared missions. Did you have your. Yeah, everything I'm curious about is how have tech transfer offices responded to this? I, I assume that there've been many conversations with them. I put cards on the table, don't have the highest opinion of the innovative-ness of tech transfer offices. And so I I'm wondering how, how have those interactions gone? There is surprisingly technophobic organizations for supposed to like, suppose to be like focusing on innovation. Yeah. Supposed to be helping out professors and researchers sort of bring innovation into the real world. But I would say on the whole, you know, not necessarily by fault of their [00:56:35] own, but rather just because tech transfer is largely a failed business model. Instructionally is not operated well. It's a couple of general councils sitting in an office that are not domain experts in any one field have typically grossly inflated ideas of what innovation is worth. It's challenging that said we've been super lucky, lucky to engage. Some amazing people at tech transfer offices that are really, I mean, and this is self selecting, right. If you're inter if you're interacting with us, probably amongst the most forward thinking let's say tech transfer people, so keep a list of them. So that like right. So that like, so, so like then, then if you can get some kind of feedback loop where, like you say, like, okay, these are the best tech transfer offices to work with. And then people start working with them and then all the other tech transfer offices start seeing. Totally. I mean, but this is what happens. [00:57:35] Like the first one does it. And then they've sort of de-risked it for the others. And this is what we see happening with every subsequent one that goes for it. It's easier to have the next conversation. We also learn more about how to work with them, how to structure these deals. I would say the main thing here is that tech transfer is largely not profitable. There's very, very few tech transfer offices in the world that are cashflow positive. Their business model is in danger. Their existence is in danger and they desperately need new ways of innovating the smart there's outside of Harvard, MIT, Stanford, Oxford, Cambridge, not that many that are really doing big things. And I think what we see is that there are people in even smaller tech transfer offices around the world that recognize this and are actually really, really hungry for a different way of doing things. And those are the people we hope to work with. But yeah, you're right. It's not the most, not the easiest. Let's say stakeholder group to engage. Yeah. Sorry, go ahead. Having said that though, [00:58:35] because we've been so this is also for example, a core role that we see that we see at molecule. Again, tech transfer can be standardized, like working with tech transfer. It doesn't matter if you are outsourcing in longevity asset or. And what we've actually made as I got developing systems that are as close as what they're used to today makes life massively easier. So the kind of things to avoid is to create the impression let's say. So even within Veit about in terms of negotiating contracts next steps around the IP it's important to realize that there's not a thousand people in a, in a discord like that will then contact the university or try to get involved in the research, make decisions. It's also then important to realize that these funds are like, it's not, they're not coming from kind of anonymous accounts in this like weird ether that is kind of the cryptocurrency space. But kind of. Give those stakeholders, the assurance that that we using the same process that they used to, that we've developed sophisticated legal [00:59:35] standards. And then all of this can run kind of through the existing banking system once it's, once it's bridged into them. And actually once you provide those assurances, it's surprisingly easy to work with them. In, in some cases, not in all of them, but I think as an organization, we, for example, I think can be much easier for them to work with them. Let's say a venture capital firm that wants to out lessons, the IP is setting up a company has, and then engages in three to six month long negotiations. I think the tech transfer offices that we have engaged, I've been pleasantly surprised how quick and easy they can actually be to work with a Dow or a decent size community. If the right structures and processes are. And like one out of every 20 is just some person who's like, oh my God, this is so cool. I also love when I play around in defy, I'm also into, it happens rarely, but when, when that happens, you're like, okay, this has got to work.[01:00:35]  And also work with, sorry, go ahead. We also work with companies that themselves have negotiated with the TTOs and they can, sub-license a stake. And either first of all, they can also work with the company molecule and the molecule can be, don't even need to know necessarily about via that way initially. Right. Molecule can have a sponsored research agreements with that startup or with the TTO. There was a company they don't TTO is, might prefer to work directly with the company, right. Or even a revenue share. We can have royalty agreements as an, as a, as an FDA as well. With, with the company a startup, right? And if, if, if the deals are too slow, we can work directly with our ups initially. And as things open up and this gets more popular and they see that there's a better place to go. So you have the, the, that was a bidder, you know, maybe other people in the crypto community can become bitters [01:01:35] for these IP NFPS. And it can be a much better way to sort of decide as a market what the value of assets are. And so if you have an asset that, that the market would this market more and more liquid market would value higher, why would you go with the traditional players when you can get much, much better terms? And so I think they will get convinced once they what they see that. Yeah. And I think also one thing that like today we funded like a new project as well. And what the research has said also that he was pleasantly surprised how quickly it went from like application to funding. So I think it was within four weeks or something, which I think is not common for like planning to funding. And I think that's also something that like and a lot of researchers are also really excited to have a community behind them that is really excited to follow the progress, to publish a process, to do interviews and the video about their research and, and connect to the other research we are funding. So I think that's [01:02:35] also like a huge value proposition to the researchers. And speaking of applications is this is a question from on Twitter. All of your proposals seem to have passed with like resounding consensus Not necessarily, not necessarily, no. It's I think there was one or two that would almost almost 50 50, but like really, like I would read on some there's like resounding like almost like a hundred percent voting in favor on two or three, there was like only 60% of voting in favor. And what I think is interesting, what I observed as a pattern is that like on the ones people voted against it was mostly in working group members voting against, but the community was like oftentimes voting in favor. So like, my feeling was like, the community wants to fund a lot of things and then things keep everything that is getting listed for funding should be funded. But then the people that in turn the, like [01:03:35] some of them who might've looked and, and help you

Meet member Niklas Rindtorff, a cancer scientist and core member of VitaDao. VitaDao is a community revolutionizing how longevity research is funded through the intersection of IP and NFTs. In this episode, Niklas explores how to open up the process of scientific funding and build a society whose healthcare system maintains health, rather than reacts to disease.

Dr. Tony Kulesa is a founder and Partner at Petri. Previously, he was the founding Director of the MIT BioMakerspace, a community biology laboratory and incubator space, and an Instructor at the MIT Department of Biological Engineering. VitaDAO is the world's first decentralized intellectual property collective, funding and commissioning research into human longevity

Panel Discussion about The Language of Communicating Longevity Hosted by VitaDAO & The Future of Longevity Speakers: Matt Kaeberlein, Morgan Levine, Karl Pfledger, Joao Pedro Magalhaes, Nathan Cheng, Laura Minquini, Max Unfried, Ariella Coler-Reilly, Avi Roy VitaDAO is the world's first decentralized intellectual property collective, funding and commissioning research into human longevity

Dr. Nir Barzilai is the director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health's (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. He is the Ingeborg and Ira Leon Rennert Chair of Aging Research, professor in the Departments of Medicine and Genetics, and member of the Diabetes Research Center and of the Divisions of Endocrinology & Diabetes and Geriatrics. Speakers: Nir Barzilai and Tim Peterson Hosts: Max Unfried and Morten Scheibye-Knudsen VitaDAO is the world's first decentralized intellectual property collective, funding and commissioning research into human longevity

On this episode, our guest is economist Paul Kohlhaas, co-founder and CEO of Molecule and co-author of the VitaDAO whitepaper. We'll head to Berlin, Germany, where Paul and his team of scientists, engineers, entrepreneurs and enthusiasts who are designing new ways to advance medicines. In Molecule's case, they're using tools not from the lab, but from the web; specifically web3 blockchain tokenized assets called non-fungible tokens (NFTs) and decentralized autonomous organizations (DAOs). The team at Molecule are leveraging these new methods to tokenize the intellectual property and then coordinate, collaborate, and even fund the conduct of scientific research and development by putting the entire process onto a blockchain. And since the intellectual property (IP) asset is digitized onto a distributed ledger, or tokenized on a blockchain, it is then very straightforward for them to be bought, sold, traded, and outlicensed on private and even public marketplaces. The decentralized ‘web3' technologies that enable this functionality are incredibly new, but are by their nature designed and intended to private, efficient, and potentially more secure way to research, develop, and commercialize new medicines. Paul and the team at Molecule are working to democratize the process of new drug development down to the last little “i” in diligence. Is this the dawn of a brave new world? Listen to find out. This is the TomorrowScale podcast. Hosted by Justin Briggs. Molecule VitaDAO "IP-NFTs for Biomedical Research: A new Biomedical Funding Paradigm." -- Tyler Golato on Medium Follow us on Twitter Listen on Your Favorite Podcast App The TomorrowScale Podcast was created to showcase scientists and entrepreneurs who are building science-based businesses, and to hear stories from the benches and in the trenches of research & development. The views expressed by the host and guests are their own, and the content of this show should not be considered legal, tax, or investing advice. Thanks to our guests for sharing their time and knowledge with us. Thank you for listening. Please science responsibly. --- Support this podcast: https://anchor.fm/tomorrowscale/support

Paul is the Co-Founder & CEO of Molecule as well as the Co-Initiator of VitaDAO. He has spent several years working in the blockchain space from organizing Ethereum meetups in South Africa to serving as Director of Business Development for ConsenSys. Paul is working on building a marketplace for drug discovery and development through the use of blockchain technology, enabling IP NFTs and bootstrapping DAOs to invest in them. Follow Paul on Twitter @paulkhls. [2:18] - How online forums led Paul to drug development and cryptocurrencies [14:34] - Paul's perspective on the US patent model and how it can be improved to foster innovation [24:05] - Molecule's use of NFTs for intellectual property ("IP NFTs") in the biotech and pharmaceutical industries [34:29] - Rethinking fundraising in the biotech and pharmaceutical industries [41:10] - Democratizing access to longevity technologies [44:12] - The future of decentralized drug development --- Support the show by checking out my sponsors: Join Levels and get personalized insights to learn about your metabolic health. Go to https://levels.link/jake. --- https://homeofjake.com

Today is a very special episode where I will be discussing Biotech and Blockchain. Now you might be asking yourself - how do blockchain and biotech have anything to do with each other? That's exactly what i thought as well when I first heard of VitaDao. But after my conversation today I'm convinced that this is a collision of industries that was absolutely necessary. Vitadao is taking the world of crypto, and the world of BioTech and smashing them together in an explosion of innovation. VitaDao is a completely decentralized autonomous organization... also know as a DAO... now there's a high likelihood that that sounds like a foreign language, and that a lot of you have never heard of a decentralized autonomous organization.. fear not, we go deep into exactly what that means in this episode.VitaDao is allowing any investor to invest in the absolute cutting edge BioTech technologies... the type of technologies that have so much potential, but carry so much risk, that the typical institutional investor or VC will pass on.This conversation blew me away... just wait until you hear what they're doing with BioTech IP and NFTs. I don't want to spoil too much but this is an episode you won't want to miss.Podcast notes and transcript available here: https://simplebiotechpodcast.com/tyler-golato-vitadao-James Ruhle, SimpleBioTechPodcast.comStay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTechIf you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

VitaDAO is a decentralized collective funding early stage longevity research. Their mission is to extend human lifespan by researching, financing, and commercializing longevity therapeutics in an open and democratic manner.We were joined by Tyler Golato and Paul Kohlhaas, co-founders of Molecule and initiators of VitaDAO to talk about how drug discovery and approval currently works, what the status of longevity research is, what role IP plays -- and how all of this could change in the future with DAOs like VitaDAO.Topics covered in this episode:Paul and Tyler's backgrounds and how they came to work on VitaDAOLongevity - thinking of aging as a diseaseWhere is the research at today?How longevity research currently takes place in the pharmaceutical industryHow VitaDAO is alleviating patency issuesThe first funded project with the Knudsen lab in Copenhagen - MoleculeHow DAOs make the decisionsEpisode links:The Molecule blogVitaDAOGoldman asks: 'Is curing patients a sustainable business model?'VitaDAO DiscordVitaDAO on TwitterMolecule on TwitterPaul on TwitterTyler on TwitterSponsors:Chorus One: Chorus One runs validators on cutting edge Proof of Stake networks such as Cosmos, Solana, Celo, Polkadot and Oasis. - https://epicenter.rocks/chorusoneParaSwap: ParaSwap aggregates all major DEXs and makes sure you beat the market price at every single swap and with the lowest slippage - http://paraswap.io/epicenter - paraswap.io/epicenterThis episode is hosted by Friederike Ernst & Meher Roy. Show notes and listening options: epicenter.tv/403

Paul Kohlhaas is the cofounder of Molecule ( https://molecule.to/ ) a collaborative platform where stakeholders in drug development work together to accelerate the process of bringing novel therapeutics to patients. He is also the co-initiator of VitaDAO ( https://www.vitadao.com/ ), a decentralized collective funding early stage longevity research. In this episode we discuss the exciting intersection of crypto and biotech, and how DAOs might replace some of the traditional funding mechanisms of scientific research. ❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc

This week, we're going to take a little bit of a break from NFTs. Instead, we're going to focus on the first biotech DAO to be created, VitaDAO. Vitalik Buterin even assisted in the creation of VitaDAO, as their thesis is beyond beneficial for humanity. They want to extend the human lifespan as far as they can. Their goal is to commercialize and fund anti-aging therapies and make humans' consciousnesses last longer. My guest for the week is a member from VitaDAO and a man who was featured on Forbes, 30 Under 30 Romania, Laurence Ion. Mr. Laurence has an extensive knowledge about longevity and the cognitive process of humans. He wants to extend lifespan beyond what it is now, because he thinks humans don't have to die so early. Throughout the episode Mr. Laurence and I discussed: Mr. Laurence's background and life beliefs, what VitaDAO is and what they're trying to do, the science behind their thesis, human longevity, and more!

The Second Community Call of VitaDAO, 02.06.21

In this interview, Greg Gillispie of Lifespan.io and Tyler Golato, co-founder and Chief Soience Officer of Molecule, discuss VitaDAO, a method of democratizing and decentralizing the development of longevity interventions with blockchain technology.

Tyler Golato is one of the masterminds behind VitaDAO, a decentralized organization that aims to fund and commercialize longevity research -- all on the Ethereum blockchain.